Column #,Trial New#,Patient #,Source,Drug,New Drug Category (target),Tumor Type,New Tumor Category,Phase,No. of treated patients,NCT Number,Trial Name,Other Trial ID #,Dose escalation,Dose,AE Notes; Combined with irAEs?,cutoff no reporting for all grade,cutoff no reporting for grades 3-4,grade 1 no reporting,If All Grade include Death (Grade 5),All Grade,Grade 3-4,Death (related to teatment),Cause of Death,Infusion-related reaction (All Grade),Infusion-related reaction (Grade 3-4),Hypersensitivity (All Grade),Hypersensitivity (Grade 3-4),Influenza-like illness (All Grade),Influenza-like illness (Grade 3-4),Pyrexia (All Grade),Pyrexia (Grade 3-4),Chills (All Grade),Chills (Grade 3-4),Fatigue (All Grade),Fatigue (Grade 3-4),Pruritus (All Grade),Pruritus (Grade 3-4),Weight decreased (All Grade),Weight decreased (Grade 3-4),Insomnia (All Grade),Insomnia (Grade 3-4),Malaise (All Grade),Malaise (Grade 3-4),Uveitis (All Grade),Uveitis (Grade 3-4),Dry mouth (All Grade),Dry mouth (Grade 3-4),Stomatitis (All Grade),Stomatitis (Grade 3-4),Mucosal inflammation   (All Grade),Mucosal inflammation   (Grade 3-4),Hypertension (All Grade),Hypertension (Grade 3-4),Hypotension (All Grade),Hypotension (Grade 3-4),Edema peripheral (All Grade),Edema peripheral (Grade 3-4),Pneumonitis (All Grade),Pneumonitis (Grade 3-4),Dyspnea (All Grade),Dyspnea (Grade 3-4),Cough (All Grade),Cough (Grade 3-4),Pneumonia (All Grade),Pneumonia (Grade 3-4),Hypoxia (All Grade),Hypoxia (Grade 3-4),Decreased appetite (All Grade),Decreased appetite (Grade 3-4),Dehydration (All Grade),Dehydration (Grade 3-4),Nausea (All Grade),Nausea (Grade 3-4),Vomiting (All Grade),Vomiting (Grade 3-4),Diarrhea (All Grade),Diarrhea (Grade 3-4),Constipation (All Grade),Constipation (Grade 3-4),Abdominal pain (All Grade),Abdominal pain (Grade 3-4),Colitis (All Grade),Colitis (Grade 3-4),Alanine aminotransferase increased (ALT) (All Grade),Alanine aminotransferase increased (ALT) (Grade 3-4),Aspartate aminotransferase increased (AST) (All Grade),Aspartate aminotransferase increased (AST) (Grade 3-4),Blood alkaline phosphatase increased  (ALP) (All Grade),Blood alkaline phosphatase increased  (ALP) (Grade 3-4),?-Glutamyl transferase increased (GGT) (All Grade),?-Glutamyl transferase increased (GGT) (Grade 3-4),Pancreatitis   (All Grade),Pancreatitis   (Grade 3-4),Lipase increased (All Grade),Lipase increased (Grade 3-4),Amylase increased (All Grade),Amylase increased (Grade 3-4),Bilirubin increase (All Grade),Bilirubin increase (Grade 3-4),Hepatitis (All Grade),Hepatitis (Grade 3-4),Increased transaminases (All Grade),Increased transaminases (Grade 3-4),Pain (All Grade),Pain (Grade 3-4),Myalgia (All Grade),Myalgia (Grade 3-4),Pain in extremity (All Grade),Pain in extremity (Grade 3-4),Back pain (All Grade),Back pain (Grade 3-4),Arthralgia (All Grade),Arthralgia (Grade 3-4),Rash (All Grade),Rash (Grade 3-4),Rash maculo-papular (All Grade),Rash maculo-papular (Grade 3-4),Erythema (All Grade),Erythema (Grade 3-4),Dry skin (All Grade),Dry skin (Grade 3-4),Vitiligo (All Grade),Vitiligo (Grade 3-4),Alopecia   (All Grade),Alopecia  (Grade 3-4),Headache (All Grade),Headache (Grade 3-4),Dizziness (All Grade),Dizziness (Grade 3-4),Asthenia (All Grade),Asthenia (Grade 3-4),Dysgeusia (All Grade),Dysgeusia (Grade 3-4),Peripheral neuropathy (All Grade),Peripheral neuropathy (Grade 3-4),Thyroiditis (All Grade),Thyroiditis (Grade 3-4),Hypothyroidism (All Grade),Hypothyroidism (Grade 3-4),Hyperthyroidism (All Grade),Hyperthyroidism (Grade 3-4),Blood thyroid-stimulating hormone (TSH) decreased (All Grade),Blood thyroid-stimulating hormone (TSH) decreased (Grade 3-4),Blood thyroid-stimulating (TSH) hormone increased (All Grade),Blood thyroid-stimulating hormone (TSH) increased (Grade 3-4),Hypophysitis (All Grade),Hypophysitis (Grade 3-4),Adrenal insufficiency (All Grade),Adrenal insufficiency (Grade 3-4),Type 1 diabetes (All Grade),Type 1 diabetes (Grade 3-4),Hypopituitarism (All Grade),Hypopituitarism (Grade 3-4),Hyperglycemia (All Grade),Hyperglycemia (Grade 3-4),Autoimmune thyroiditis (All Grade),Autoimmune thyroiditis (Grade 3-4),Blood creatinine increased (All Grade),Blood creatinine increased (Grade 3-4),White blood cell decreased (All Grade),White blood cell decreased (Grade 3-4),Platelet count decreased (All Grade),Platelet count decreased (Grade 3-4),Anemia (All Grade),Anemia (Grade 3-4),Lymphopenia (All Grade),Lymphopenia (Grade 3-4),Neutropenia (All Grade),Neutropenia (Grade 3-4),Hyponatremia (All Grade),Hyponatremia (Grade 3-4),Hypophosphatemia (All Grade),Hypophosphatemia (Grade 3-4)
1,1,33,2010-Brahmer-J Clin Oncol,Nivolumab,PD-1,Advanced solid tumors,Mixed cancer types,1,6,441337,,CA209-001 ST  MDX1106-01 ,Yes,1 mg/kg Q4W,Treatment-related/Drug-related; Grade ? 2,0,0,1,No,,,,,0,0,0,0,,,1,0,,,0,0,,,,,,,,,,,,,0,0,,,0,0,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,0,0,,,,,,,,,,,,,,,0,0,,,,,,,,,1,0,0,0,0,0,,,,
2,1,,2010-Brahmer-J Clin Oncol,Nivolumab,PD-1,Advanced solid tumors,Mixed cancer types,1,6,441337,,CA209-001 ST  MDX1106-01 ,,3 mg/kg Q4W,Treatment-related/Drug-related; Grade ? 2,0,0,1,No,,,,,0,0,1,0,,,0,0,,,3,0,,,,,,,,,,,,,0,0,,,0,0,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,0,0,,,,,,,,,,,,,,,0,0,,,,,,,,,0,0,2,0,0,0,,,,
3,1,,2010-Brahmer-J Clin Oncol,Nivolumab,PD-1,Advanced solid tumors,Mixed cancer types,1,21,441337,,CA209-001 ST  MDX1106-01 ,,10 mg/kg Q4W,Treatment-related/Drug-related; Grade ? 2,0,0,1,No,,,,,2,0,0,0,,,0,0,,,3,1,,,,,,,,,,,,,1,0,,,0,0,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,1,0,,,,,,,,,,,,,,,1,0,,,,,,,,,1,0,6,1,0,0,,,,
4,2,259,2012-Topalian-N Engl J Med,Nivolumab,PD-1,Advanced tumors,Mixed cancer types,1,79,730639,,CA209-003  MDX1106-03 ,Yes,1 mg/kg Q2W,Treatment-related; ? 1% All patients,2,2,0,Unknown,39,5,,,,,,,,,,,,,,,13,0,,,,,,,,,,,,,,,,,,,,,3,2,,,,,,,,,,,,,,,,,15,0,,,,,,,4,0,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,16,0,,,,,,,3,0,2,0,,,,,,,,,,,,,2,0,0,0,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5,2,,2012-Topalian-N Engl J Med,Nivolumab,PD-1,Advanced tumors,Mixed cancer types,1,50,730639,,CA209-003  MDX1106-03 ,,3 mg/kg Q2W,Treatment-related; ? 1% All patients,2,2,0,Unknown,19,2,,,,,,,,,,,,,,,4,0,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,,,,,,3,0,,,,,,,2,0,2,1,,,,,,,,,,,,,,,,,,,,,,,,,,,4,0,,,,,,,2,0,0,0,,,,,,,,,,,,,1,0,1,0,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6,2,,2012-Topalian-N Engl J Med,Nivolumab,PD-1,Advanced tumors,Mixed cancer types,1,130,730639,,CA209-003  MDX1106-03 ,,10 mg/kg Q2W,Treatment-related; ? 1% All patients,2,2,0,Unknown,50,11,,,,,,,,,,,,,,,9,1,,,,,,,,,,,,,,,,,,,,,5,1,,,,,,,,,,,,,,,,,12,3,,,,,,,4,2,3,1,,,,,,,,,,,,,,,,,,,,,,,,,,,11,0,,,,,,,0,0,1,0,,,,,,,,,,,,,3,1,1,1,,,3,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7,3,72,2014-Topalian-J Clin Oncol,Nivolumab,PD-1,Melanoma,Melanoma,1,35,730639,,CA209-003  MDX1106-03 ,Yes,1 mg/kg Q2W,Treatment-related; ? 3% All patients,2,2,0,Unknown,34,5,0,,2,0,,,,,1,0,,,12,1,8,0,1,0,,,,,,,4,1,,,,,,,0,0,,,,,,,2,0,,,,,0,0,,,3,0,1,0,10,0,,,5,0,,,3,0,2,0,,,,,,,,,,,,,,,,,1,0,2,0,,,,,4,0,13,0,,,,,,,4,0,,,,,,,,,,,,,,,1,0,,,,,2,0,,,,,,,,,,,,,,,1,0,3,0,,,1,0,,,,,1,1
8,3,,2014-Topalian-J Clin Oncol,Nivolumab,PD-1,Melanoma,Melanoma,1,17,730639,,CA209-003  MDX1106-03 ,,3 mg/kg Q2W,Treatment-related; ? 3% All patients,2,2,0,Unknown,15,6,0,,3,0,,,,,0,0,,,8,0,3,0,3,0,,,,,,,1,0,,,,,,,1,0,,,,,,,1,0,,,,,2,0,,,3,0,1,0,2,0,,,1,1,,,1,0,1,0,,,,,,,,,,,,,,,,,1,0,1,0,,,,,1,0,2,0,,,,,,,2,0,,,,,,,,,,,,,,,1,0,,,,,0,0,,,,,,,,,,,,,,,1,0,1,1,,,3,2,,,,,2,0
9,3,,2014-Topalian-J Clin Oncol,Nivolumab,PD-1,Melanoma,Melanoma,1,20,730639,,CA209-003  MDX1106-03 ,,10 mg/kg Q2W,Treatment-related; ? 3% All patients,2,2,0,Unknown,14,5,0,,0,0,,,,,2,0,,,4,0,2,0,0,0,,,,,,,1,0,,,,,,,2,0,,,,,,,0,0,,,,,2,0,,,2,1,2,1,4,2,,,2,1,,,0,0,0,0,,,,,,,,,,,,,,,,,0,0,0,0,,,,,0,0,4,0,,,,,,,0,0,,,,,,,,,,,,,,,2,1,,,,,1,1,,,,,,,,,,,,,,,1,0,1,0,,,0,0,,,,,0,0
10,4,23,2015-Ansell-N Engl J Med,Nivolumab,PD-1,Hodgkin's lymphoma,Hematologic malignancy,1,23,1592370,,CA209-039 ,No,3 mg/kg Q2W,Drug-related in ? 5% All patients; Drug-related serious adverse events,1,1,0,Unknown,18,5,0,, ,  , ,  , ,  ,3,0, ,  ,3,0,3,0, ,  , ,  ,,, ,  , ,  ,2,1, ,  , ,  , ,  , ,  ,1,1, ,  ,2,0,,,,, ,  , ,  ,3,0, ,  ,3,0, ,  , ,  , ,  , ,  , ,  , ,  , ,  ,1,1,2,1,,,,,,,,, ,  , ,  , ,  , ,  , ,  ,5,0, ,  , ,  ,,  , ,  , ,  , ,  , ,  , ,  , ,  , ,  , ,  ,2,0,,,,,,, ,  , ,  ,,,,,,,,, ,  , ,  ,4,0, ,  ,2,1, ,  ,,,2,0
11,5,287,2015-Borghaei-N Engl J Med,Nivolumab,PD-1,Nonsquamous NSCLC,Lung cancer,3,287,1673867,CheckMate 057,CA209-057  2012-002472-14,No,3 mg/kg Q2W,Treatment-related; ? 10% Patients treated with Nivolumab or Docetaxel,28,28,0,Unknown,199,30,0,,8,0,1,0,  ,  ,8,0,  ,  ,46,3,24,0,  ,  ,  ,  ,,,  ,  ,  ,  ,3,1,2,0,  ,  ,  ,  ,8,0,4,3,  ,  ,  ,  ,,,,,30,0,  ,  ,34,2,15,0,22,2,13,0,  ,  ,  ,  ,9,0,9,1,2,0,2,2,,,  ,  ,,,,,,,,,4,0,7,1,  ,  ,  ,  ,16,0,27,1,,,4,0,,  ,  ,  ,1,0,  ,  ,  ,  ,29,1,5,0,3,0,  ,  ,19,0,4,0,1,0,6,0,  ,  ,  ,  ,,,,,  ,  ,,,5,0,0,0,  ,  ,6,1,  ,  ,1,0,  ,  ,  ,  
12,6,131,2015-Brahmer-N Engl J Med,Nivolumab,PD-1,Squamous NSCLC,Lung cancer,3,131,1642004,CheckMate 017,CA209-017  2011-004792-36 ,No,3 mg/kg Q2W,Treatment-related; ? 5% Patients treated with Nivolumab or Docetaxel,6,6,0,Unknown,76,9,0,,1,0,0,0,,,6,0,,,21,1,,,,,,,,,,,,,,,3,0,,,,,2,0,6,1,,,,,,,,,14,1,,,12,0,4,0,10,0,2,0,2,0,1,1,2,0,2,0,,,,,,,,,,,,,,,,,,,2,0,,,,,7,0,5,0,,,1,0,,,,,0,0,,,2,0,13,0,,,1,0,,,5,0,,,,,,,,,,,,,,,,,,,4,0,0,0,,,2,0,,,1,0,,,,
14,7,129,2015-Gettinger-J Clin Oncol,Nivolumab,PD-1,NSCLC,Lung cancer,1,33,730639,,CA209-003  MDX1106-03,Yes,1 mg/kg Q2W,Treatment-related; ? 3% All patients,3,3,0,Yes,21,5,2,Pneumonitis,1,0,,,,,3,0,0,0,8,3,3,0,,,,,,,,,,,,,0,0,,,,,,,3,2,0,0,1,0,,,,,4,1,,,3,1,0,0,4,0,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,3,1,2,0,,,1,0,0,0,,,,,,,,,,,,,0,0,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,,,1,0,,,,,2,0
15,7,,2015-Gettinger-J Clin Oncol,Nivolumab,PD-1,NSCLC,Lung cancer,1,37,730639,,CA209-003  MDX1106-03,,3 mg/kg Q2W,Treatment-related; ? 3% All patients,3,3,0,Yes,25,5,1,Pneumonitis,0,0,,,,,2,0,1,0,7,0,0,0,,,,,,,,,,,,,0,0,,,,,,,1,0,3,0,2,0,,,,,4,0,,,5,0,2,0,4,0,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,1,0,0,0,,,2,0,3,0,,,,,,,,,,,,,0,0,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,1,1,,,,,1,0
16,7,,2015-Gettinger-J Clin Oncol,Nivolumab,PD-1,NSCLC,Lung cancer,1,59,730639,,CA209-003  MDX1106-03,,10 mg/kg Q2W,Treatment-related; ? 3% All patients,3,3,0,Yes,45,8,0,Pneumonitis,3,0,,,,,3,0,3,0,16,1,8,0,,,,,,,,,,,,,4,0,,,,,,,4,1,3,0,2,0,,,,,8,0,,,4,0,2,0,5,1,,,1,1,,,,,,,,,,,,,,,,,,,,,,,,,0,0,2,0,,,2,0,6,0,,,,,,,,,,,,,7,0,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,2,0,,,,,2,0
17,8,20,2015-Hamanishi-J Clin Oncol,Nivolumab,PD-1,Ovarian,Other cancer,2,10,,,UMIN Clinical Trials Registry UMIN000005714,Yes,1 mg/kg Q2W,Treatment-related of special interest; ? 20% All patients,3,3,0,Unknown,9,4,0,,,,,,,,2,1,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,1,6,0,,,,,,,,,,,,,,,,,,,,,,,,,5,0,,,3,0,,,,,,,,,,,,,,,,,,,,,4,0,,,,,,,,,,,,,,,,,,,,,,,,,3,2,4,3,,,,,,
18,8,,2015-Hamanishi-J Clin Oncol,Nivolumab,PD-1,Ovarian,Other cancer,2,10,,,UMIN Clinical Trials Registry UMIN000005714,,3 mg/kg Q2W,Treatment-related of special interest; ? 20% All patients,3,3,0,Unknown,10,4,0,,,,,,,,4,0,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,2,0,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,2,1,,,,,,,,,,,,,,,,,,,,,4,0,,,,,,,,,,,,,,,,,,,,,,,,,1,1,3,0,,,,,,
19,9,34,2015-McDermott-J Clin Oncol,Nivolumab,PD-1,RCC,GU cancer,1,18,730639,,CA209-003  MDX1106-03 ,Yes,1 mg/kg Q2W,Treatment-related; ? 3% All patients,1,1,0,Unknown,15,2,0,,,,,,2,0,2,0,0,0,6,0,4,0,1,0,,,,,,,1,0,,,,,,,,,,,,,3,0,,,,,,,3,0,,,1,0,,,5,0,,,2,0,,,2,0,0,0,0,0,,,,,,,,,,,,,,,,,,,1,0,,,2,1,7,0,,,,,3,0,,,,,0,0,,,,,1,0,1,0,,,3,0,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0
20,9,,2015-McDermott-J Clin Oncol,Nivolumab,PD-1,RCC,GU cancer,1,16,730639,,CA209-003  MDX1106-03 ,,10 mg/kg Q2W,Treatment-related; ? 3% All patients,1,1,0,Unknown,14,4,0,,,,,,0,0,1,0,2,0,8,0,2,1,1,0,,,,,,,1,0,,,,,,,,,,,,,0,0,,,,,,,0,0,,,1,0,,,1,0,,,0,0,,,2,1,2,0,2,1,,,,,,,,,,,,,,,,,,,1,0,,,1,0,2,0,,,,,1,0,,,,,2,0,,,,,1,0,1,0,,,0,0,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,2,2
21,10,406,2015-Motzer-N Engl J Med,Nivolumab,PD-1,RCC,GU cancer,3,406,1668784,CheckMate 025,CA209-025  2011?005132?26,No,3 mg/kg Q2W,Treatment-related; ? 10% Patients treated with Nivolumab or Everolimus,40,40,0,Unknown,319,76,0,,,,,,,,,,,,134,10,57,0,,,,,,,,,,,8,0,11,0,,,,,17,0,16,6,30,3,36,0,,,,,48,2,,,57,1,,,50,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,41,2,,,,,,,,,,,,,,,,,11,0,,,,,,,,,,,,,,,,,,,,,9,5,,,,,,,,,32,7,,,,,,,,
22,11,54,2015-Motzer-J Clin Oncol,Nivolumab,PD-1,RCC,GU cancer,2,54,1354431,,CA209-010 ,Yes,10 mg/kg Q3W,Treatment-related in ? 10% Patients in any group; Potential immune-mediated,5,5,0,Unknown,42,7,0,,,,9,0,,,,,,,19,0,6,0,,,,,,,,,6,0,,,,,,,,,,,3,0,,,,,,,,,2,0,,,7,0,,,8,0,,,,,,,3,0,2,0,,,,,,,,,,,,,,,,,,,,,,,,,8,1,7,0,,,,,7,0,,,,,,,,,,,,,,,,,4,0,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,,,
23,12,117,2015-Rizvi-Lancet Oncol,Nivolumab,PD-1,NSCLC,Lung cancer,2,117,1721759,CheckMate 063,CA209-063  2012-003965-16 ,No,3 mg/kg Q2W,"Treatment-related, ? 5% All patients",5,5,0,Unknown,87,20,2,1 for hypoxic pneumonia; 1 for ischaemic stroke,,,,,,,,,,,38,5,7,1,,,,,,,,,7,0,,,,,,,,,,,6,4,6,0,,,,,,,22,0,,,18,0,7,0,12,3,6,0,,,,,,,,,,,,,,,,,,,,,,,,,,,6,1,,,,,,,13,1,,,,,,,,,,,,,,,14,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7,1,,,,,,,,
24,13,206,2015-Robert-N Engl J Med2,Nivolumab,PD-1,Melanoma,Melanoma,3,206,1721772,CheckMate 066,CA209-066  2012?003718?16,No,3 mg/kg Q2W,Treatment-related; ? 2% Patients in either group,4,4,0,Unknown,153,24,0,,9,0,6,0,,,15,0,,,41,0,35,1,,,,,1,0,,,,,,,,,,,1,0,,,,,,,6,0,,,,,11,0,,,34,0,13,1,33,2,22,0,8,0,,,,,2,1,,,,,,,,,,,,,,,,,,,9,0,6,0,,,12,0,31,1,6,1,13,0,9,0,22,0,7,0,9,0,,,21,0,6,0,,,,,9,0,7,1,,,,,,,,,,,,,,,,,,,1,0,0,0,9,0,5,0,0,0,,,,
26,14,98,2016-Antonia-Lancet Oncol,Nivolumab,PD-1,SCLC,Lung cancer,2-Jan,98,1928394,CheckMate 032,,No,3 mg/kg Q2W,Treatment-related; ? 10% Patients in any cohort (Grade 12) and all events (Grade 34),9,9,0,No,52,13,0,,,,,,,,,,,,11,1,11,0,,,,,,,,,,,,,,,,,,,,,3,1,1,0,,,,,,,6,0,,,7,0,3,1,7,0,,,,,,,3,1,3,0,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,1,0,,,,,,,,,,,,,,,,,,,,,3,0,2,0,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,2,0,,
27,15,69,2016-Choueiri-Clin Cancer Res,Nivolumab,PD-1,RCC,GU cancer,3,22,1358721,,,Yes,2 mg/kg Q3W,Treatment-related; ? 15% Patients in all treatment groups (any grade) and ? 2 patients in any treatment group (select AEs with potential immunologic causes),3,3,0,Unknown,22,8,,,1,0,,,,,,,,,13,2,4,0,,,,,,,,,,,,,,,,,,,,,0,0,,,8,0,,,,,,,,,7,0,,,4,0,6,1,,,0,0,0,0,0,0,,,,,,,,,,,0,0,,,,,,,,,,,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,,,,,,,,4,0,,,,,,,,,,,,,,
28,15,,2016-Choueiri-Clin Cancer Res,Nivolumab,PD-1,RCC,GU cancer,3,23,1358721,,,,10 mg/kg Q3W,Treatment-related; ? 15% Patients in all treatment groups (any grade) and ? 2 patients in any treatment group (select AEs with potential immunologic causes),3,3,0,Unknown,23,13,,,4,0,,,,,,,,,15,0,4,0,,,,,,,,,,,,,,,,,,,,,2,1,,,4,0,,,,,,,,,6,0,,,5,1,4,0,,,2,1,2,1,3,2,,,,,,,,,,,2,1,,,,,,,,,,,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,3,0,,,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,,,,,
29,15,,2016-Choueiri-Clin Cancer Res,Nivolumab,PD-1,RCC,GU cancer,3,24,1358721,,,,10 mg/kg Q3W,Treatment-related; ? 15% Patients in all treatment groups (any grade) and ? 2 patients in any treatment group (select AEs with potential immunologic causes),3,3,0,Unknown,24,12,,,5,1,,,,,,,,,13,1,4,0,,,,,,,,,,,,,,,,,,,,,3,0,,,5,0,,,,,,,,,10,0,,,9,1,6,0,,,2,2,2,0,2,0,,,,,,,,,,,2,0,,,,,,,,,,,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,,,,,
30,16,236,2016-Ferris-N Engl J Med,Nivolumab,PD-1,Head and neck carcinoma,Other cancer,3,236,2105636,CheckMate 141,CA209-141  2013-003622-86,No,3 mg/kg Q2W,Treatment-related; ? 5% Patients in either group,11,11,0,Yes,139,31,2,1 for pneumonitis; 1 for hypercalcemia/pulmonary embolism,,,,,,,,,,,33,5,17,0,4,0,,,,,,,,,5,1,3,0,,,,,,,,,,,,,,,,,17,0,,,20,0,8,0,16,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,18,0,,,,,7,0,,,0,0,,,,,10,1,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12,3,,,0,0,,,,
32,17,52,2016-Gettinger-J Clin Oncol,Nivolumab,PD-1,NSCLC,Lung cancer,1,52,1454102,,,No,3 mg/kg Q2W,Treatment-related; ? 5% All Patients; Combined with treatment-related irAEs,2,2,0,Yes,37,10,0,,2,0,1,0,,,,,,,15,0,6,0,,,,,,,,,,,,,,,,,,,,,3,1,,,,,,,,,,,,,7,0,3,0,6,1,3,0,,,,,1,1,1,1,,,,,,,,,,,,,,,,,,,,,,,,,5,0,10,2,,,2,0,,,,,,,,,,,,,,,,,2,0,3,0,1,0,,,2,0,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,
33,18,81,2016-Lesokhin-J Clin Oncol,Nivolumab,PD-1,Hematologic malignancy,Hematologic malignancy,1b,81,1592370,,,Yes,mixed,Drug-related; ? 5% Patients (any grade) and all events (grade ? 3); Combined with drug-related irAEs,4,4,0,Yes,53,17,1,pneumonitis/ARDS,,,,,,,6,0,,,14,0,7,0,,,,,,,,,,,,,3,1,,,,,,,9,3,,,,,,,,,7,0,,,,,,,6,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,1,,,,,5,3,3,1,3,1,,,,
34,19,78,2016-Sharma-Lancet Oncol,Nivolumab,PD-1,Urothelial carcinoma,GU cancer,2-Jan,78,1928394,CheckMate 032,,No,3 mg/kg Q2W,Treatment-related; ? 10% Patients (any grade) and all events (grade 3-4),7,7,0,No,63,17,2,1 for pneumonitis;1 for thrombocytopenia,,,,,,,,,,,28,2,23,0,,,,,,,,,,,,,,,,,,,,,,,6,2,,,,,,,,,,,10,1,,,,,,,,,1,1,,,1,1,,,,,,,,,,,,,,,,,,,,,,,1,1,9,0,,,14,2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5,1,,,,,3,1,,,8,0,5,2,3,2,,2,,
35,20,61,2016-Weber-Cancer Immu Res,Nivolumab,PD-1,Melanoma,Melanoma,2-Jan,61,1176461,,MCC-15400  NCI-P-7997  CA209-006/007  10-15526-99-01,No,3 mg/kg Q2W,Drug-related; Any irAEs or > 5% of total patients,3,3,0,No, ,,0,,5,0,,,0,0,10,0,5,0,33,1,35,1,3,0,,,,,,,4,0,,,,,,,,,,,0,0,4,0,1,0,,,,,,,2,1,10,0,5,0,20,0,4,0,3,0,0,0,4,0,3,0,3,0,,,1,0,0,0,,,,,,,,,1,0,1,0,1,0,,,11,0,,,48,4,2,0,4,0,,,,,8,0,,,,,,,,,,,5,0,3,0,,,,,,,4,2,,,,,0,0,,,3,0,4,0,1,0,8,1,2,1,2,0,9,1,,
36,21,12,2017-Ben-Ami-Cancer,Nivolumab,PD-1,Uterus leiomyosarcoma,Other cancer,2,12,2428192,,NCI-2014-02403 ,No,3 mg/kg Q2W,"All grade ? 3 AEs including unrelated, possible, probable, definite realted to drug",12,0,0,Yes,,9,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,3,,1,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
37,22,267,2017-Carbone-N Engl J Med,Nivolumab,PD-1,NSCLC,Lung cancer,3,267,2041533,CheckMate 026,,No,3 mg/kg Q2W,Treatment-related; ? 10% Patients in either group,26,26,0,Unknown,190,47,2,one each from multiorgan failure and pneumonitis,,,,,,,,,,,56,3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,32,1,,,31,1,15,0,37,3,9,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26,2,,,,,,,,,,,,,,,8,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,9,1,,,,,,,,
38,23,33,2017-El-Khoueiry-Lancet,Nivolumab,PD-1,Hepatocellular carcinoma,GI cancer,2-Jan,10,1658878,CheckMate 040,,Yes,1 mg/kg Q2W,"Treatment-related; ? 5% of all patients, any grade",1,1,0,Unknown,8,5,0,,,,,,,,,,,,1,0,0,0,0,0,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,1,0,,,0,0,,,0,0,,,,,,,1,0,3,2,,,,,,,4,4,4,1,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,,,,,2,0,,
39,23,,2017-El-Khoueiry-Lancet,Nivolumab,PD-1,Hepatocellular carcinoma,GI cancer,2-Jan,10,1658878,CheckMate 040,,,3 mg/kg Q2W,"Treatment-related; ? 5% of all patients, any grade",1,1,0,Unknown,9,2,0,,,,,,,,,,,,0,0,1,0,0,0,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,0,0,,,1,0,,,1,0,,,,,,,2,1,1,1,,,,,,,2,1,2,1,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,0,0,,
40,23,,2017-El-Khoueiry-Lancet,Nivolumab,PD-1,Hepatocellular carcinoma,GI cancer,2-Jan,13,1658878,CheckMate 040,,,10 mg/kg Q2W,"Treatment-related; ? 5% of all patients, any grade",1,1,0,Unknown,11,0,0,,,,,,,,,,,,0,0,3,0,2,0,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,1,0,,,1,0,,,1,0,,,,,,,2,0,4,0,,,,,,,2,0,2,0,,,,,,,,,,,,,,,,,4,0,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,,,1,0,,
41,24,330,2017-Kang-Lancet,Nivolumab,PD-1,Gastric or gastro-oesophageal junction cancer ,GI cancer,3,330,2267343,ATTRACTION-2,ONO-4538-12,No,3 mg/kg Q2W,Treatment-related ? 2% Patients in Nivolumab group; Treatment-related of special interest ? 1 patients in Nivolumab group,6,6,0,Unknown,141,34,5,"hepatitis (n=1), cardiac arrest (n=1), death (unknown cause; n=1), exertional dyspnoea (n=1), and pneumonia (n=1)",,,,,,,8,1,,,18,2,30,0,,,,,13,0,,,,,,,,,,,,,,,1,1,,,,,,,,,16,4,,,14,0,,,23,2,,,,,2,1,7,1,11,2,,,,,,,,,,,,,1,1,,,,,,,,,,,,,19,0,4,0,,,,,,,,,,,,,,,,,,,,,10,0,2,0,,,,,,,,,,,1,1,,,1,0,,,,,,,,,,,,,,,,
42,25,65,2017-Kudo-Lancet Oncol,Nivolumab,PD-1,Oesophageal squamous-cell carcinoma,GI cancer,2,65,,,ONO-4538-07/JapicCTI-No.142422,No,3 mg/kg Q2W,Treatment-related; ?10% Patients if no grade 3-4 events or <10% if any grade 3-4 event (grade 1-2) and all events (grade 3-4),6,6,0,No,47,11,0,,,,,,,,,,,,5,1,,,,,,,,,,,,,,,,,0,0,,,,,,,1,1,,,,,,,6,2,2,2,,,,,9,0,1,0,,,,,,,,,0,0,0,0,,,,,,,,,,,,,,,,,,,,,,,5,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,2,,,,,,,,,1,1,1,1,,
43,26,268,2017-Larkin-J Clin Oncol,Nivolumab,PD-1,Melanoma,Melanoma,3,268,1721746,CheckMate 037,,No,3 mg/kg Q2W,Treatment-related; ? 5% All patients,13,13,0,Unknown,206,37,,,,,,,,,14,0,,,86,3,59,0,,,,,,,,,,,,,,,,,,,,,,,15,0,,,,,,,18,0,,,33,0,,,49,1,,,,,,,16,3,20,2,,,,,,,,,,,,,,,,,,,,,,,,,22,0,36,1,19,1,,,15,0,29,0,,,,,,,15,0,,,,,,,19,0,,,,,,,,,,,,,,,,,,,,,,,,,20,3,,,,,,,,
44,27,17,2017-Maruyama-Cancer Sci,Nivolumab,PD-1,rrHL,Hematologic malignancy,2,17,,,JapicCTI-142755,No,3 mg/kg Q2W,Drug-related; ? 10% All patients or immunerelated,1,1,0,Unknown,17,4,0,,,,,,,,,,,,3,0,6,0,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,2,0,,,6,1,,,,,,,,,,,4,0,2,0,,,,,,,,,5,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,1,,
45,28,37,2017-Morris-Lancet Oncol,Nivolumab,PD-1,Anal cancer,GI cancer,2,37,2314169,,,No,3 mg/kg Q2W,Treatment-related/Drug-related; All AEs,0,0,0,No,,,0,,,,,,,,,,,,25,1,,,6,0,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,9,0,,,2,0,,,8,0,10,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6,0,11,1,,,,,,,,,,,,,,,,,,,,,,,3,1,,,,,,,,,,,,,,,4,0,,,,,,,,,26,2,,,,,,,,
47,29,74,2017-Overman-Lancet Oncol,Nivolumab,PD-1,Colorectal cancer ,GI cancer,2,74,2060188,CheckMate 142,,No,3 mg/kg Q2W,Treatment-related; ? 10% Patients (grade 1-2) and all events (grade 3-4),7,7,0,No,51,15,0,,,,,,,,4,0,,,17,1,10,0,,,,,,,,,,,3,1,,,,,,,,,,,,,,,,,,,,,,,7,0,,,16,1,,,2,1,1,1,4,1,5,0,,,1,1,,,9,6,4,2,,,,,,,1,1,,,,,,,4,0,8,0,5,1,,,4,0,,,,,,,,,5,0,,,,,,,7,0,,,,,,,,,1,1,,,,,,,,,2,1,,,,,,,2,1,,,,,,
48,30,270,2017-Sharma-Lancet Oncol,Nivolumab,PD-1,Urothelial carcinoma,GU cancer,2,270,2387996,,,No,3 mg/kg Q2W,Treatment-related; ? 5% All patients and select (immunomediated),13,13,0,No,170,47,3,1 for pneumonitis;1 for acute respiratory failure;1 for cardiovascular failure, ,,,,,,15,0,,,45,5,25,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,22,0,,,19,1,,,24,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16,3,,,,,,,,,,,,,,,16,4,,,,,,,21,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
49,31,452,2017-Weber-N Engl J Med,Nivolumab,PD-1,Melanoma,Melanoma,3,452,2388906,CheckMate 238,,No,3 mg/kg Q2W,Treatment-related; ? 10% Patients in either group,45,45,0,Unknown,385,65,0,,,,,,,,7,0,,,156,2,105,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,68,1,,,110,7,,,29,0,,,28,5,25,2,,,,,,,,,,,,,,,,,,,,,,,,,57,1,90,5,24,0,,,,,,,,,44,1,,,57,1,,,,,,,49,1,,,,,,,7,2,,,,,,,,,,,,,,,,,,,,,,,,,,
50,32,14,2017-Yamamoto-Invest New Drugs,Nivolumab,PD-1,Solid tumors,Mixed cancer types,1,3,441337,,,Yes,1 mg/kg Q2W,Drug-related; ? 2 Patients,1,1,0,Unknown (All Grades AND Grades ?3),3,0,0,,,,,,,,1,0,,,0,0,0,0,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,0,0,0,0,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,,,0,0,,,,,,,1,0,,,,,,
51,32,,2017-Yamamoto-Invest New Drugs,Nivolumab,PD-1,Solid tumors,Mixed cancer types,1,5,441337,,,,3 mg/kg Q2W,Drug-related; ? 2 Patients,1,1,0,Unknown (All Grades AND Grades ?3),5,1,0,,,,,,,,1,0,,,1,0,1,0,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,1,0,1,0,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,,0,0,,,,,,,2,1,,,,,,
52,32,,2017-Yamamoto-Invest New Drugs,Nivolumab,PD-1,Solid tumors,Mixed cancer types,1,6,441337,,,,10 mg/kg Q2W,Drug-related; ? 2 Patients,1,1,0,Unknown (All Grades AND Grades ?3),6,0,0,,,,,,,,2,0,,,2,0,2,0,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,,,,,1,0,2,0,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,,2,0,,,,,,,5,0,,,,,,
53,33,23,2017-Yamazaki-Cancer Sci,Nivolumab,PD-1,Melanoma,Melanoma,2,23,,,JapicCTI-142533,No,3 mg/kg Q2W,Treatment-related AEs in ?10% Patients; Treatment-related serious AEs; Treatment-related select AEs,2,2,0,Unknown (All Grades AND Grades ?3),20,3,0,,0,0,,,,,,,,,,,6,0,3,0,,,6,0,,,,,,,,,,,,,,,,,,,,,,,,,3,0,,,,,,,,,,,,,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,0,,,3,0,,,,,9,0,,,,,,,,,,,,,,,6,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
54,34,243,2018-Armand-J Clin Oncol,Nivolumab,PD-1,Hodgkin's lymphoma,Hematologic malignancy,2,243,2181738,CheckMate 205,,No,3 mg/kg Q2W,Drug-related; ? 10% Patients (any grade) and ? 2% Patients (grade 3-4),24,4,0,Yes,,,0,,34,1,,,,,22,0,,,56,2,25,0,,,,,,,,,,,,,,,,,,,,,,,10,1,15,0,5,3,,,,,,,25,0,21,1,37,2,11,0,18,2,,,18,8,17,5,6,1,,,,,17,11,11,5,,,,,,,,,12,0,,,6,0,20,0,29,2,,,,,,,,,,,16,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8,1,,,15,8,,,,
56,35,42,2018-D'Angelo-Lancet Oncol,Nivolumab,PD-1,Sarcoma,Other cancer,2,42,2500797,,Alliance A091401,No,3 mg/kg Q2W,? 10% Patients (grade 1-2) or ? 1 Patient (grade 3-5),4,0,0,Yes,,3,0,,,,,,,,4,0,,,25,1,0,0,,,,,,,,,,,,,,,,,0,0,,,,,10,0,13,0,,,0,0,,,2,2,12,0,1,1,5,1,6,1,,,,,0,0,0,0,0,0,,,,,2,2,,,,,,,,,25,2,,,,,,,,,4,0,,,,,,,,,,,,,,,,,,,,,,,6,0,,,,,,,,,0,0,,,,,0,0,,,1,1,,,1,1,12,4,,,,,,,,
57,36,22,2018-Forde-N Engl J Med,Nivolumab,PD-1,NSCLC,Lung cancer,2,22,2259621,,,No,3 mg/kg Q2W,Treatment-related,0,0,0,Yes,5,1,0,,1,0,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,3,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
58,37,129,2018-Gettinger-J Clin Oncol,Nivolumab,PD-1,NSLCL,Lung cancer,1,129,730639,CA209-003,,Yes,mixed,Treatment-related (with potential immunologic cause),0,0,0,Yes,91,22,1,Sepsis,7,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
59,38,391,2018-Hellmann-N Engl J Med,Nivolumab,PD-1,NSCLC,Lung cancer,3,391,2477826,CheckMate 227,,No,240 mg Q2W,Treatment-related; ? 10% Patients (any grade) in any group,39,39,0,Yes,251,74,2,"1 pneumonitis with sepsis, 1 neutropenia with sepsis",,,,,,,,,,,43,2,30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,25,0,,,21,1,10,1,44,3,6,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,43,3,,,,,,,,,,,,,,,29,2,,,,,,,25,1,,,,,,,,,,,,,,,,,,,,,,,,,11,2,,,1,0,,,,
60,39,313,2018-Hodi-Lancet Oncol,Nivolumab,PD-1,Melanoma,Melanoma,3,313,1844505,CheckMate 067,,No,3 mg/kg Q2W,Treatment-related; ? 10% Patients (any grade) or ? 2% Patients (grade 3-4) in any group,31,6,0,Yes,270,71,1,Neutropenia,,,,,,,21,0,,,114,3,69,1,,,,,,,,,,,,,,,,,,,,,,,19,1,,,,,,,35,0,1,0,41,0,22,1,69,9,,,,,8,3,13,4,14,3,,,,,,,29,16,21,7,,,0,0,2,1,,,,,,,,,32,1,74,1,16,2,,,,,31,1,,,24,0,,,,,,,,,,,32,0,14,0,,,,,2,1,4,2,,,,,,,,,,,,,,,,,,,,,,,,
62,40,59,2018-Janjigian-J Clin Oncol,Nivolumab,PD-1,Esophagogastric cancer,GI cancer,2-Jan,59,1928394,CheckMate-032 ,,No,3 mg/kg Q2W,Treatment-related; ? 15% Patients (any grade) in any group,8,8,0,Yes,41,10,0,,,,,,,,,,,,20,1,10,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9,0,,,,,,,9,1,,,,,,,5,2,7,3,,,,,,,,,,,,,,,,,,,,,,,,,,,5,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
63,41,100,2018-Lee-Lung Cancer,Nivolumab,PD-1,NSCLC,Lung cancer,2,100,2175017,,,No,3 mg/kg Q2W,Treatment-related; ? 1 Patient (any grade and grade ? 3),0,0,0,Unknown,,,1,Pneumonitis,1,0,1,0,,,,,,,,,19,0,,,,,,,,,,,,,,,,,,,,,3,2,,,,,,,,,,,,,,,,,8,1,,,,,,,8,3,7,2,,,2,1,,,,,,,1,0,,,,,,,,,,,,,,,9,0,,,1,0,,,,,,,,,,,,,,,,,1,0,3,0,2,0,,,1,0,,,,,,,,,,,,,1,0,,,,,,,,,,,,,,
64,42,41,2018-Long-Lancet Oncol,Nivolumab,PD-1,Melanoma brain metastases,Melanoma,2,41,2374242,,,No,3 mg/kg Q2W,Treatment-related; ? 10% Patients (any grade) or ? 1 Patient (grade 3-4) in any group,4,0,0,Yes,29,4,0,,,,,,,,,,,,10,0,4,0,,,,,,,,,,,,,,,,,,,,,1,0,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,1,0,,,6,2,,,,,0,0,,,,,8,0,6,0,,,,,,,3,0,,,6,1,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
65,43,45,2018-Ma-J Clin Oncol,Nivolumab,PD-1,Nasopharyngeal carcinoma,Other cancer,2,45,2339558,,NCI-9742,No,3 mg/kg Q2W,All treatment-related,0,0,0,Yes,,10,1,Sepsis,,,,,,,,,,,15,1,,,3,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,0,,,5,1,,,,,1,1,4,2,6,1,,,,,,,,,3,0,,,,,,,,,4,0,,,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,6,0,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,1,1,,
66,44,10,2018-Omuro-Neuro Oncol,Nivolumab,PD-1,Glioblastoma,Other cancer,1,10,2017717,CheckMate 143,,No,3 mg/kg Q2W,Treatment-related; ? 2 Patients in any arm or treatment-related serious AEs,1,1,0,Yes,9,0,0,,,,,,,,0,0,,,3,0,2,0,,,,,,,,,,,,,,,,,,,,,1,0,,,0,0,,,,,0,0,,,3,0,1,0,1,0,,,,,0,0,0,0,0,0,,,,,0,0,2,0,1,0,0,0,,,,,,,,,,,,,,,2,0,0,0,,,,,,,,,2,0,1,0,0,0,,,,,,,2,0,1,0,,,,,,,,,,,,,0,0,0,0,,,,,0,0,0,0,,,,,,,,
67,45,34,2018-Quispel-Janssen-J Thorac Oncol,Nivolumab,PD-1,Pleural mesothelioma,Other cancer,2,34,2497508,,,No,3 mg/kg Q2W,All treatment-related,0,0,0,Yes,26,9,1,Pneumonitis,2,0,,,,,3,0,,,10,0,5,0,,,,,,,,,,,,,,,,,,,,,4,2,,,,,,,,,,,,,3,1,1,1,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
68,46,109,2018-Ready-J Thorac Oncol,Nivolumab,PD-1,SCLC,Lung cancer,2-Jan,109,1928394,CheckMate 32,,No,3 mg/kg Q2W,Treatment-related; ? 5% Patients (any grade),5,5,0,Yes,60,13,1,Pneumonitis,,,,,,,,,,,11,1,14,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6,1,,,8,0,,,7,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
69,47,495,2015-Garon-N Engl J Med,Pembrolizumab,PD-1,NSCLC,Lung cancer,1,6,1295827,KEYNOTE-001,P07990  MK-3475-001  2011-002371-42 ,Yes,2 mg/kg Q3W,Treatment-related; ? 2% Patients in any group,0,0,0,Yes,,,0,,0,,,,,,0,,0,,0,,1,,1,,,,,,,,,,,,,,,,,,,,0,,1,,0,,,,,,0,,,,0,,0,,0,,0,,,,,,0,,0,,,,,,,,,,,,,,,,,,,,0,,,,,,0,,0,,0,,,,0,,,,,,0,,,,0,,,,,,,,1,,0,,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,
70,47,,2015-Garon-N Engl J Med,Pembrolizumab,PD-1,NSCLC,Lung cancer,1,287,1295827,KEYNOTE-001,P07990  MK-3475-001  2011-002371-42 ,,10 mg/kg Q3W,Treatment-related; ? 2% Patients in any group,5,5,0,Yes,,,1,Pneumonitis/Interstitial lung disease,3,,,,,,12,,6,,62,,31,,8,,,,,,,,,,,,,,,,,,,,13,,11,,8,,,,,,36,,,,23,,8,,26,,4,,,,,,7,,10,,,,,,,,,,,,,,,,,,,,7,,,,,,25,,30,,2,,,,7,,,,,,6,,,,12,,,,,,,,14,,6,,,,,,,,,,,,,,,,,,,,,,,,10,,,,,,,,,
71,47,,2015-Garon-N Engl J Med,Pembrolizumab,PD-1,NSCLC,Lung cancer,1,202,1295827,KEYNOTE-001,P07990  MK-3475-001  2011-002371-42 ,,10 mg/kg Q2W,Treatment-related; ? 2% Patients in any group,4,4,0,Yes,,,0,,7,,,,,,9,,4,,34,,21,,10,,,,,,,,,,,,,,,,,,,,5,,9,,4,,,,,,16,,,,14,,6,,14,,6,,,,,,4,,5,,,,,,,,,,,,,,,,,,,,6,,,,,,20,,18,,4,,,,11,,,,,,3,,,,12,,,,,,,,19,,3,,,,,,,,,,,,,,,,,,,,,,,,11,,,,,,,,,
72,48,41,2015-Le-N Engl J Med,Pembrolizumab,PD-1,Advanced solid tumors,Mixed cancer types,2,41,1876511,,J1365  MK-3475-016  NA_00085756,No,10 mg/kg Q2W,> 5% Patients,2,2,0,Unknown,40,17,,,,,,,,,5,0,6,0,13,0,,,,,3,0,,,,,5,0,,,,,,,,,,,1,0,6,0,4,0,,,,,4,0,,,5,0,,,10,2,8,0,10,0,,,3,2,,,,,,,6,0,,,,,,,,,,,14,0,6,0,,,,,7,0,,,,,,,5,0,,,,,7,0,4,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8,7,8,8,,,3,3,,
73,49,23,2015-Patnaik-Clin Cancer Res,Pembrolizumab,PD-1,Advanced solid tumors,Mixed cancer types,1,10,1295827,KEYNOTE-001,P07990  MK-3475-001  2011-002371-42 ,Yes,10 mg/kg Q2W,Treatment-related; ? 1 Patient,0,0,0,Unknown,4,0,,,,,,,,,,,,,4,0,1,0,1,0,0,0,,,,,,,,,,,,,1,0,,,0,0,0,0,,,,,,,2,0,,,1,0,0,0,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,0,0,,,,,,,,,0,0,,,,,,,,,0,0,0,0,0,0,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
74,49,,2015-Patnaik-Clin Cancer Res,Pembrolizumab,PD-1,Advanced solid tumors,Mixed cancer types,1,7,1295827,KEYNOTE-001,P07990  MK-3475-001  2011-002371-42 ,,2 mg/kg Q3W,Treatment-related; ? 1 Patient,0,0,0,Unknown,7,0,,,,,,,,,,,,,3,0,1,0,0,0,0,0,,,,,,,,,,,,,0,0,,,0,0,1,0,,,,,,,0,0,,,2,0,0,0,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,0,0,,,,,,,,,1,0,,,,,,,,,1,0,0,0,0,0,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
75,49,,2015-Patnaik-Clin Cancer Res,Pembrolizumab,PD-1,Advanced solid tumors,Mixed cancer types,1,6,1295827,KEYNOTE-001,P07990  MK-3475-001  2011-002371-42 ,,10 mg/kg Q3W,Treatment-related; ? 1 Patient,0,0,0,Unknown,4,0,,,,,,,,,,,,,2,0,0,0,0,0,1,0,,,,,,,,,,,,,0,0,,,0,0,0,0,,,,,,,2,0,,,2,0,1,0,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,1,0,,,,,,,,,0,0,,,,,,,,,0,0,1,0,0,0,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
76,50,357,2015-Ribas-Lancet Oncol,Pembrolizumab,PD-1,Melanoma,Melanoma,2,178,1704287,KEYNOTE-002,P08719  MK-3475-002 ,Yes,2 mg/kg Q3W,Treatment-related; ? 5% Patients in any group,8,8,0,No,120,19,0,,,,,,,,,,,,40,2,37,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8,0,,,8,0,2,1,15,0,5,0,,,,,,,,,,,,,,,,,,,,,,,,,,,9,2,,,,,13,1,21,0,5,1,,,9,0,10,0,5,0,,,,,6,1,,,2,0,,,9,0,,,,,,,,,,,,,,,,,,,,,,,0,0,5,1,,,1,0,,,,
77,50,,2015-Ribas-Lancet Oncol,Pembrolizumab,PD-1,Melanoma,Melanoma,2,179,1704287,KEYNOTE-002,P08719  MK-3475-002 ,,10 mg/kg Q3W,Treatment-related; ? 5% Patients in any group,8,8,0,No,132,25,0,,,,,,,,,,,,52,1,42,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17,2,,,16,1,10,1,19,2,9,0,,,,,,,,,,,,,,,,,,,,,,,,,,,7,0,,,,,11,1,18,0,10,1,,,9,0,9,0,1,0,,,,,8,1,,,0,0,,,13,0,,,,,,,,,,,,,,,,,,,,,,,1,0,7,0,,,1,0,,,,
78,51,555,2015-Robert-N Engl J Med,Pembrolizumab,PD-1,Melanoma,Melanoma,3,278,1866319,KEYNOTE-006,MK-3475-006  2012-004907-10 ,Yes,10 mg/kg Q2W,Treatment-related; ? 1% Patients in any group and AEs of special interest (autoimmune or immune-related),2,2,0,Yes (All Grades AND Grades 3-5),221,37,0,,,,2,0,2,0,11,0,3,0,58,0,40,0,3,0,6,0,,,1,0,20,0,,,1,0,3,2,,,3,0,1,0,4,0,10,0,,,,,17,0,,,28,0,10,1,47,7,7,0,10,0,4,4,12,0,14,0,2,0,,,,,,,,,6,0,3,3,,,,,19,1,6,1,7,0,26,0,41,0,10,0,8,0,6,0,25,0,4,0,9,0,8,0,32,1,10,0,,,,,28,1,17,0,3,0,2,0,1,1,,,1,1,,,,,,,4,0,,,,,3,2,,,3,0,,,,
79,51,,2015-Robert-N Engl J Med,Pembrolizumab,PD-1,Melanoma,Melanoma,3,277,1866319,KEYNOTE-006,MK-3475-006  2012-004907-10 ,,10 mg/kg Q3W,Treatment-related; ? 1% Patients in any group and AEs of special interest (autoimmune or immune-related),2,2,0,Yes (All Grades AND Grades 3-5),202,28,0,,,,3,0,6,0,3,0,0,0,53,1,39,0,3,0,1,0,,,3,0,11,0,,,3,0,1,1,,,1,0,5,1,8,1,12,0,,,,,18,0,,,31,1,5,0,40,3,5,0,5,0,8,5,4,1,6,1,3,0,,,,,,,,,1,0,5,5,,,,,6,0,1,1,5,0,32,1,37,0,6,1,3,0,8,0,31,0,1,0,6,0,1,0,31,0,5,0,,,,,24,0,7,0,3,0,3,0,2,1,,,1,1,,,,,,,3,0,,,,,6,0,,,1,0,,,,
80,52,31,2016-Armand-J Clin Oncol,Pembrolizumab,PD-1,Classical Hodgkin Lymphoma,Hematologic malignancy,1b,31,1953692,KEYNOTE-013,,No,10 mg/kg Q2W,Treatment-related; ? 2 Patients of any grade,1,1,0,Unknown,21,5,0,,,,,,,,,,2,0,2,0,,,,,,,,,,,,,,,,,,,,,,,3,0,2,0,,,,,,,2,0,,,4,0,2,0,5,0,2,0,,,1,1,2,1,2,1,,,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,,,,,,,,,2,0,,,,,2,0,5,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
81,53,132,2016-Chow-J Clin Oncol,Pembrolizumab,PD-1,Head and neck carcinoma,Other cancer,1b,132,1848834,KEYNOTE-012,,No,200 mg Q3W,Treatment-related; ? 10% Patients (grade 1-2) and any event (grade 3-4),13,13,0,No,82,12,0,,,,,,,,,,,,28,0,,,,,,,,,,,,,2,1,,,,,,,,,4,2,,,,,,,,,11,2,1,1,7,1,,,,,,,2,1,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,14,0,,,,,,,,,,,1,1,,,2,1,,,,,,,,,,,,,,,,,,
82,54,682,2016-Herbst-Lancet,Pembrolizumab,PD-1,NSCLC,Lung cancer,3-Feb,339,1905657,KEYNOTE-010,MK-3475-010  2012-004391-19  132355,Yes,2 mg/kg Q3W,Treatment-related ? 1% of patients in any group; Special interest ? 2 patients in the pembrolizumab groups,3,3,0,Yes (All Grades AND Grades 3-5),215,43,3,2 for pneumonitis; 1 for pneumonia,1,0,1,0,1,0,10,1,2,0,46,4,25,0,5,0,1,0,4,0,,,5,0,13,0,1,0,,,1,0,5,0,14,6,7,2,9,0,5,3,,,46,3,0,0,37,1,12,0,24,2,13,0,5,0,4,3,16,2,10,2,3,0,4,0,3,2,,,,,,,1,1,,,2,0,9,0,2,0,5,1,13,0,29,1,6,1,,,4,0,,,3,0,8,0,5,0,20,1,4,0,2,0,2,0,25,0,10,0,,,3,0,1,1,2,0,1,1,,,,,,,6,0,0,0,,,10,3,4,0,1,0,,,0,0
83,54,,2016-Herbst-Lancet,Pembrolizumab,PD-1,NSCLC,Lung cancer,3-Feb,343,1905657,KEYNOTE-010,MK-3475-010  2012-004391-19  132355,,10 mg/kg Q3W,Treatment-related ? 1% of patients in any group; Special interest ? 2 patients in the pembrolizumab groups,3,3,0,Yes (All Grades AND Grades 3-5),226,55,3,1 for pneumonitis; 1 for pneumonia; 1 for myocardial infarction,4,0,0,0,6,0,14,0,4,0,49,6,32,0,10,1,5,0,10,0,,,3,0,7,1,1,0,,,2,0,4,0,12,6,14,2,2,0,5,3,,,33,1,2,0,31,2,13,1,22,0,10,0,2,0,2,1,8,1,7,0,8,2,1,1,0,0,,,,,,,2,0,,,2,0,10,0,4,0,4,0,19,2,44,1,3,0,,,14,0,,,2,0,6,0,6,0,19,2,7,0,3,0,0,0,23,0,15,1,,,4,0,1,1,3,1,2,1,,,,,,,7,0,3,0,,,14,1,2,0,1,0,,,3,2
84,55,36,2016-Goldberg-Lancet Oncol,Pembrolizumab,PD-1,Melanoma,Melanoma,2,18,2085070,,,No,10 mg/kg Q2W,Neurological; Treatment-related non-neurological,0,0,0,No,,,0,,,,,,,,,,,,8,0,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,2,0,,,,,,,,,,,,,3,0,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
85,55,,2016-Goldberg-Lancet Oncol,Pembrolizumab,PD-1,NSCLC,Lung cancer,2,18,2085070,,,,10 mg/kg Q2W,Neurological; Treatment-related non-neurological,0,0,0,No,,,0,,,,,,,,,,,,6,1,,,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,1,0,,,,,,,,,,,,,4,0,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
86,56,39,2016-Muro-Lancet Oncol,Pembrolizumab,PD-1,Gastric cancer,GI cancer,1b,39,1848834,KEYNOTE-012,MK-3475-012 3475-012  2012-005771-14  142453 ,No,10 mg/kg Q2W,Treatment-related; ? 10% Patients (grade 1-2) and all events (grade 3-5),3,3,0,Yes,26,5,0,,,,,,,,,,,,7,2,5,0,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,5,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,0,,,,,,,,,,,,,,,,,,,,,3,1,,,5,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
87,57,32,2016-Nanda-J Clin Oncol,Pembrolizumab,PD-1,TNBC,Other cancer,1b,32,1848834,KEYNOTE-012,,No,10 mg/kg Q2W,Treatment-related; ? 2 Patients (any grade) and ? 1 Patients (grade 3-5),1,0,0,Yes,18,5,1,DIC accompanied by grade 4 decreased blood fibrinogen,,,,,,,1,1,,,6,0,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5,0,,,4,0,,,,,,,2,0,2,0,,,,,,,,,,,,,,,,,,,6,0,,,,,6,0,,,,,2,0,,,,,,,2,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,1,1,,,,,,
88,58,26,2016-Nghiem-N Engl J Med,Pembrolizumab,PD-1,Merkel cell Carcinoma,Other cancer,2,26,2267603,,NCI-2014-00848  NCI-2014-00848  MK-3475  CITN-09  CITN-09  U01CA154967,No,2 mg/kg Q3W,Drug-related,0,0,0,No,20,4,,,,,,,,,,,2,0,12,0,1,0,1,0,,,,,,,1,0,,,,,2,0,2,0,,,1,0,,,2,0,,,,,1,0,,,1,0,,,1,0,,,,,,,2,2,4,3,1,0,,,,,,,,,,,,,,,,,2,0,,,,,1,0,1,0,,,,,,,,,2,0,1,0,1,0,1,0,,,,,,,,,,,,,,,,,1,1,,,,,1,1,,,1,1,,,1,0,1,0,,,,,2,2,,
89,59,154,2016-Reck-N Engl J Med,Pembrolizumab,PD-1,NSCLC,Lung cancer,3,154,2142738,KEYNOTE-024,MK-3475-024 2014-000323-25  142728 ,No,200 mg Q3W,Treatment-related; ?10% Patients in either group,15,15,0,Yes (All Grades AND Grades 3-5),113,41,1,sudden death of unknown cause,,,,,,,16,0,,,16,2,,,,,,,,,,,,,4,0,,,,,,,,,,,,,,,,,,,14,0,,,15,0,4,1,22,6,6,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,3,0,1,0,0,0,8,3,,,1,0,,,,
90,60,655,2016-Ribas-JAMA,Pembrolizumab,PD-1,Melanoma,Melanoma,1b,655,1295827,KEYNOTE-001,P07990  MK-3475-001  2011-002371-42 ,Yes,mixed,Treatment-related/Drug-related; ? 5% Patients,32,32,0,Unknown,544,92,0,,,,,,,,42,1,41,0,245,12,174,2,,,,,,,,,,,,,,,,,,,,,,,41,4,48,1,,,,,56,1,,,97,2,33,3,115,6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,60,0,,,,,107,0,161,4,,,,,,,69,0,,,51,2,,,63,4,,,,,,,46,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
91,61,60,2016-Seiwert-Lancet Oncol,Pembrolizumab,PD-1,Head and neck carcinoma,Other cancer,1b,60,1848834,KEYNOTE-012,,No,10 mg/kg Q2W,Treatment-related,0,0,0,No,38,10,0,,,,,,,,,,,,13,1,7,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,1,,,,,,,2,2,2,2,,,,,,,,,,,,,,,,,,,,,,,,,,,4,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,,,2,2,,
92,62,7,2016-Shimizu-Invest New Drugs,Pembrolizumab,PD-1,Advanced solid tumors,Mixed cancer types,1,7,1840579,,MK-3475,Yes,10 mg/kg Q2W,Treatment-related/Drug-related,0,0,0,Yes,,,0,,,,,,,,1,0,,,0,0,,,1,0,,,1,0,,,,,,,,,,,,,,,1,0,1,0,,,,,,,,,1,0,1,0,,,,,,,,,,,2,1,2,1,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,1,0,,,,,,,,,1,0,,,1,0,1,1,,
94,63,25,2017-Alley-Lancet Oncol,Pembrolizumab,PD-1,Pleural mesothelioma,Other cancer,1b,25,2054806,KEYNOTE-028,,No,10 mg/kg Q2W,Treatment-related,0,0,0,No,16,5,0,,1,0,,,,,2,1,,,6,0,4,0,,,,,,,,,3,0,,,2,0,,,,,,,,,2,1,1,0,,,,,3,1,,,6,0,,,2,0,2,0,,,,,1,1,1,0,1,0,1,0,,,,,,,,,,,,,,,1,0,,,,,5,0,1,0,2,0,,,2,0,,,,,2,0,,,2,0,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,0,,,,,1,1,,,,
95,64,370,2017-Balar-Lancet Oncol,Pembrolizumab,PD-1,Urothelial carcinoma,GU cancer,2,370,2335424,KEYNOTE-052,,No,200 mg Q3W,Treatment-related; ? 10% Patients (grade 1-2) and all events (grade 3-5),36,36,0,Yes,229,57,1,myositis,,,,,,,14,1,,,62,8,52,1,,,,,,,,,,,,,,,,,2,1,,,5,2,,,,,1,1,,,31,2,3,1,28,1,,,28,2,,,,,7,4,11,3,13,3,7,5,,,,,1,1,,,5,1,2,2,,,,,,,,,2,1,9,1,36,1,10,1,,,,,,,,,,,5,1,16,3,,,,,2,1,,,,,,,,,1,1,2,2,3,2,1,1,4,1,,,7,1,,,,,8,1,,,,,3,2,2,2
96,65,266,2017-Bellmunt-N Engl J Med,Pembrolizumab,PD-1,Advanced urothelial carcinoma,GU cancer,3,266,2256436,KEYNOTE-045,,No,200 mg Q3W,Treatment-related in ? 10% Patients in either group; Event of interest (immune-related cause),26,26,0,Yes (All Grades AND Grades 3-5),162,40,4,"1 for pneumonitis;1 for 
 urinary
tract obstruction;1 for malignant
neoplasm progression; 1 for unspecified
cause",2,0,,,,,,,,,37,3,52,0,,,,,,,,,,,,,,,,,,,,,11,6,,,,,,,,,23,0,,,29,1,,,24,3,6,0,,,6,3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15,1,,,1,0,2,0,17,0,10,0,,,,,,,1,1,,,,,,,,,,,,,,,9,2,,,1,1,,,,
97,66,171,2017-Bauml-J Clin Oncol,Pembrolizumab,PD-1,Head and neck cancer,Other cancer,2,171,2255097,KEYNOTE-055,,No,200 mg Q3W,Treatment-related; ? 2% Patients,3,3,0,Yes (All Grades AND Grades 3-5),109,26,1,pneumonitis,,,,,,,,,,,30,1,8,0,6,0,,,,,,,,,,,,,,,,,,,6,2,,,5,0,,,,,9,0,,,11,0,,,10,1,,,,,,,7,0,11,4,4,2,,,,,,,,,,,,,,,,,5,0,,,,,6,0,9,0,4,1,,,,,,,,,,,4,0,,,,,5,0,,,16,0,,,,,,,,,,,,,,,,,,,,,,,,,6,3,,,,,4,1,,
98,67,210,2017-Chen-J Clin Oncol,Pembrolizumab,PD-1,Hodgkin's lymphoma,Hematologic malignancy,2,210,2453594,KEYNOTE-087,,No,200 mg Q3W,Treatment-related; ? 5% All patients,10,10,0,No, , ,0,,,,,,,,22,1,5,0,19,1,8,0,,,2,0,,,,,,,,,,,,,,,,,,,7,2,12,1,,,,,,,,,12,0,8,0,15,2,6,0,,,,,,,,,,,,,,,,,,,,,,,,,,,5,0,,,4,0,9,1,16,0,,,,,,,,,,,13,0,,,3,0,,,,,,,26,1,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,11,5,,,,
99,68,25,2017-Ding-Blood,Pembrolizumab,PD-1,CLL,Hematologic malignancy,2,25,2332980,,MC1485/NCI-2014-02561 ,No,200 mg Q3W,Drug-related; ? 5% Patients,1,1,0,No,25,15,,,,,,,,,2,1,2,0,5,2,,,,,,,,,,,,,,,,,,,,,,,,,6,2,7,0,,,2,2,,,,,5,0,3,0,3,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11,5,10,5,,,9,5,,,,
100,69,23,2017-Doi-J Clin Oncol,Pembrolizumab,PD-1,Esophageal carcinoma,GI cancer,1b,23,2054806,KEYNOTE-028,,No,10 mg/kg Q2W,Treatment-related; ? 1 Patient,0,0,0,No,9,4,0,,,,,,,,,,,,1,0,1,0,,,,,,,,,,,1,0,,,,,,,,,,,,,,,1,0,,,2,1,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,1,,,,,,,,,,,,,,,1,0,,,,,,,1,0,1,0,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,
101,70,24,2017-Frenel-J Clin Oncol,Pembrolizumab,PD-1,Cervical cancer,Other cancer,1b,24,2054806,KEYNOTE-028,,No,10 mg/kg Q2W,Treatment-related; ? 2 Patients of any grade,1,1,0,No,18,5,0,,,,,,,,4,0,,,2,0,2,0,,,,,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5,2,,,,,2,0,,,,,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,,,,,,
102,71,947,2017-Gangadhar-J Immunother,Pembrolizumab,PD-1,Melanoma,Melanoma,,947,2083484,KEYNOTE-030,,No,2 mg/kg Q3W,Treatment-related of interest based on possible immune etiology,0,0,0,Unknown,181,29,0,,,,,,,,,,,,,,42,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17,,41,,,,,,,,,,,,,,,,,,,,,,,,9,,2,,,,,,2,,7,,,,1,,,,,,,,,,,,,,,,,,,,,
103,72,27,2017-Hsu-J Clin Oncol,Pembrolizumab,PD-1,Nasopharyngeal carcinoma,Other cancer,1b,27,2054806,KEYNOTE-028,,No,10 mg/kg Q2W,Treatment-related/Drug-related; ? 5% Patients (any grade) and any event (grade 3-5),1,1,0,Yes (All Grades AND Grades 3-5),20,8,1,sepsis,,,,,,,,,,,5,0,7,0,,,,,,,,,,,,,,,,,,,,,3,2,,,2,0,,,,,,,,,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,6,1,2,0,,,,,,,7,0,,,,,,,,,,,,,,,,,,,,,,,5,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
104,73,24,2017-Ott-J Clin Oncol,Pembrolizumab,PD-1,Endometrial cancer,Other cancer,1b,24,2054806,KEYNOTE-028,,No,10 mg/kg Q2W,Treatment-related; ? 1 Patient,0,0,0,Unknown,13,4,0,,,,,,,,3,1,1,1,5,0,4,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,0,,,,,,,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,2,0,,,,,,,,,,,,,,,,,2,1,,,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,2,1,,,,,1,1,,
105,74,25,2017-Ott-Ann Oncol,Pembrolizumab,PD-1,Anal canal carcinoma,GI cancer,1b,25,2054806,KEYNOTE-028,,No,10 mg/kg Q2W,Treatment-related; ? 2 Patients (any grade) and ? 1 Patient (grade 3-4),1,0,0,Unknown,16,3,0,,,,2,0,,,,,,,4,0,,,,,,,,,,,2,0,2,0,,,,,,,,,,,,,,,,,,,,,,,3,0,2,0,4,1,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,,,,1,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,
106,75,24,2017-Ott-J Clin Oncol2,Pembrolizumab,PD-1,SCLC,Lung cancer,1b,24,2054806,KEYNOTE-028,,No,10 mg/kg Q2W,Treatment-related; ? 5% Patients,1,1,0,No,16,1,0,,,,,,,,,,,,3,0,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,3,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,,,4,0,4,0,,,,,2,0,,,,,,,,,4,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
107,76,23,2017-O'Neil-PLoS One,Pembrolizumab,PD-1,Colorectal carcinoma,GI cancer,1b,23,2054806,KEYNOTE-028,,No,10 mg/kg Q2W,Treatment-related,0,0,0,Yes,8,1,0,,,,,,,,,,,,3,0,1,0,,,,,,,,,,,2,0,,,,,,,,,,,,,,,,,,,1,0,,,1,0,1,0,1,0,1,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,1,0,,,,,1,0,,,,,1,0,,,,,,,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
108,77,33,2017-Plimack-Lancet Oncol,Pembrolizumab,PD-1,Urothelial cancer,GU cancer,1b,33,1848834,KEYNOTE-012,,No,10 mg/kg Q2W,Treatment-related; ? 10% Patients (grade 1-2) and all events (grade 3-4),3,3,0,No,20,5,0,,,,,,,,,,,,6,0,,,,,,,,,,,,,,,,,,,,,4,0,,,,,,,,,,,,,1,1,,,,,,,,,,,,,,,2,1,,,,,,,,,,,,,,,,,,,2,1,,,,,,,,,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,
109,78,555,2017-Schachter-Lancet,Pembrolizumab,PD-1,Melanoma,Melanoma,3,278,1866319,KEYNOTE-006,,Yes,10 mg/kg Q2W,Treatment-related; ? 10% Patients in any group,27,27,0,Unknown,229,47,1,sepsis,,,,,,,,,,,79,1,56,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,36,0,,,54,7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,35,0,44,0,,,,,,,,,,,,,,,,,,,,,,,30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
110,78,,2017-Schachter-Lancet,Pembrolizumab,PD-1,Melanoma,Melanoma,3,277,1866319,KEYNOTE-006,,,10 mg/kg Q3W,Treatment-related; ? 10% Patients in any group,27,27,0,Unknown,213,46,0,,,,,,,,,,,,64,3,55,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,37,0,,,46,3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,38,0,48,0,,,,,,,,,,,,,,,,,,,,,,,23,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
111,79,84,2017-Tawbi-Lancet Oncol,Pembrolizumab,PD-1,Bone sarcoma,Other cancer,2,42,2301039,SARC028,,No,200 mg Q3W,Events with maximum grade 2 occurring in <10% of patients overall have been suppressed,0,0,0,Yes,40,21,2,"1 for Neoplasms benign, malignant and unspecified (incl cysts and polyps)-other, specify; 1 for Respiratory, thoracic and mediastinal disorders-other, specify",,,,,,,4,0,3,0,10,0,2,0,4,0,4,0,,,,,,,,,,,2,0,2,1,,,2,0,8,1,12,0,,,3,2,,,1,1,7,1,4,1,5,0,7,0,3,0,,,7,0,10,0,16,4,,,,,,,,,2,1,,,,,5,0,3,1,5,2,6,0,0,0,,,2,0,,,,,,,,,1,0,,,,,,,,,,,2,0,3,0,,,,,,,0,0,,,,,6,0,,,5,1,6,2,6,3,18,6,,,,,14,1,2,1
112,79,,2017-Tawbi-Lancet Oncol,Pembrolizumab,PD-1,Soft-tissue sarcoma,Other cancer,2,42,2301039,SARC028,,,200 mg Q3W,Events with maximum grade 2 occurring in <10% of patients overall have been suppressed,0,0,0,Yes,38,21,4,"1 for Duodenal perforation; 1 for Sepsis; 1 for Neoplasms benign, malignant and unspecified (incl cysts and polyps)-other, specify; 2 for Death NOS",,,,,,,5,0,2,0,24,2,4,0,8,0,3,0,,,,,,,,,,,1,1,1,0,,,2,1,11,2,12,0,,,1,1,,,0,0,15,0,7,1,10,1,10,1,10,2,,,6,1,5,0,13,0,,,,,,,,,1,0,,,,,3,0,3,0,7,1,13,2,7,0,,,2,0,,,,,,,,,8,1,,,,,,,,,,,2,0,4,0,,,,,,,2,1,,,,,11,2,,,7,1,4,1,6,1,23,3,,,,,13,2,1,0
113,80,42,2017-Yamazaki-Cancer Chemother Pharmacol,Pembrolizumab,PD-1,Melanoma,Melanoma,1b,42,2180061,KEYNOTE-041,MK-3475,No,2 mg/kg Q3W,Treatment-related; ? 2 Patients,1,1,0,Yes (All Grades AND Grades 3-5),34,8,2,1 for unknown cause and 1 for cerebral hemorrhage, ,,,,,,,,,,,,6,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,3,0,,,2,0,2,1,2,0,3,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6,0,,,2,0,3,0,,,,,,,,,,,,,,,4,0,2,0,,,,,2,1,,,,,,,,,,,,,,,,,2,2,,,,,,,,
114,81,18,2017-Zinzani-Blood,Pembrolizumab,PD-1,rrPMBCL,Hematologic malignancy,1b,18,1953692,KEYNOTE-013,,No,mixed,Drug-related adverse events,0,0,0,Unknown,11,2,0,,,,,,,,2,0,,,2,0,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,2,0,,,2,0,1,0,2,0,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,,,,
115,82,107,2018-Adams-Ann Oncol,Pembrolizumab,PD-1,TNBC,Other cancer,2,107,2447003,KEYNOTE-086,,No,200 mg Q3W,Treatment-related ? 5% Patients or immune-mediated ? 1 Patient,5,5,0,Yes,103,22,0,,3,0,,,,,,,,,35,1,11,0,,,,,,,,,,,,,,,,,,,,,7,1,,,,,,,,,13,0,,,19,1,,,12,3,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10,0,,,,,,,,,,,,,,,,,11,0,,,,,,,20,0,9,0,,,,,,,,,1,1,,,,,,,,,,,,,,,,,,,,,,
116,83,12,2018-Adra-Ann Oncol,Pembrolizumab,PD-1,Germ cell tumors,GU cancer,2,12,2499952,,GU14-206,No,200 mg Q3W,All common and ? grade 3 AEs observed,0,0,0,Yes,,,0,,,,,,2,0,,,,,6,0,,,,,,,,,,,,,,,,,,,,,,,,,2,0,2,0,,,,,,,,,5,0,4,0,3,0,2,0,3,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,1,1,,,,,,,,
117,84,33,2018-Cho-J Clin Oncol,Pembrolizumab,PD-1,Thymic epithelial tumor,Other cancer,2,33,2607631,,,No,200 mg Q3W,Treatment-related; > 5% Patients (any grade) in any histologic group or ? 1 Patient (irAE) ,1,1,0,,,,,,,,,,,,,,,,7,0,3,0,,,,,,,,,,,,,,,,,,,2,0,,,11,0,6,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,,,,,,,4,4,,,,,3,0,,,4,0,,,2,0,,,,,,,,,,,,,,,,,,,,,3,1,,,,,,,,,,,,,,,,,,,,,,,,,,,3,1,,,,,,,,
118,85,26,2018-Cohen-Am J Clin Oncol,Pembrolizumab,PD-1,Salivary gland carcinoma,Other cancer,1b,26,2054806,KEYNOTE-028,,No,10 mg/kg Q2W,Treatment-related; ? 2 Patients (any grade) or ? 1 Patient (grade 3-5),1,0,0,Yes,22,3,1,Interstitial lung disease,,,,,,,,,,,8,0,4,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,0,,,3,0,,,4,0,,,,,,,2,0,2,0,,,,,,,,,,,2,0,1,1,,,,,2,0,,,,,3,0,,,,,,,,,,,,,,,,,2,0,,,,,,,3,0,,,,,,,,,,,,,,,,,,,,,,,,,2,1,,,,,,,,
119,86,246,2018-Cohen-Lancet,Pembrolizumab,PD-1,Head and neck carcinoma,Other cancer,3,246,2252042,KEYNOTE-040,,No,200 mg Q3W,Treatment-related ? 10% Patients or immune-related (regardless of attribution to treatment) ? 1% Patients in either group,24,24,0,Yes,155,33,1,Severe skin reaction,8,1,,,,,,,,,31,4,,,,,,,,,,,,,6,1,9,1,,,,,,,10,3,,,,,,,,,,,,,12,0,,,20,4,,,,,2,0,,,,,,,,,,,,,,,,,2,1,,,,,,,,,,,,,19,1,,,,,,,,,1,0,,,,,18,1,,,,,,,37,1,5,0,,,,,,,,,,,,,,,,,,,,,,,17,1,,,,,,,,
120,87,509,2018-Eggermont-N Engl J Med,Pembrolizumab,PD-1,Melanoma,Melanoma,3,509,2362594,,EORTC 1325 ,No,200 mg Q3W,Treatment-related or irAE; ? 10% Patients,50,50,0,Yes,396,75,1,Myositis,,,,,,,,,,,,,90,0,,,,,,,2,0,,,,,,,,,,,,,17,4,30,1,,,,,,,,,,,58,0,,,97,4,,,,,19,10,,,,,,,,,2,1,,,,,,,9,7,,,,,,,,,,,61,3,82,1,,,,,,,24,0,,,,,,,,,,,,,16,0,73,0,52,1,,,,,11,3,5,1,5,5,,,,,,,,,,,,,,,,,,,,,,
121,88,259,2018-Fuchs-JAMA Oncol,Pembrolizumab,PD-1,Gastric or gastro-oesophageal junction cancer ,GI cancer,2,259,2335411,KEYNOTE-059,,No,200 mg Q3W,Treatment-related; ? 5% Patients (any grade),12,12,0,Yes,156,46,0,,,,,,,,,,,,49,6,23,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19,0,,,18,2,,,17,3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15,1,22,2,,,,,,,,,,,,,,,,,,,,,,,20,1,,,,,,,,,,,,,,,,,,,,,,,,,18,7,,,,,,,,
122,89,45,2018-Gadgeel-J Thorac Oncol,Pembrolizumab,PD-1,SCLC,Lung cancer,2,45,,,,No,200 mg Q3W,Treatment-related; ? 10% Patients (any grade),4,4,0,Yes,,,1,Acute coronary syndrome,,,,,,,,,,,18,0,10,0,,,,,,,,,,,,,,,,,,,,,,,9,0,10,0,,,,,,,,,12,0,,,7,0,10,0,5,0,,,,,6,0,,,,,,,,,,,,,,,,,,,,,,,6,0,,,8,0,,,,,,,,,,,6,0,9,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
123,90,40,2018-Giaccone-Lancet Oncol,Pembrolizumab,PD-1,Thymic carcinoma,Other cancer,2,40,2364076,,,No,200 mg Q3W,All treatment-related,0,0,0,Yes,,,0,,,,,,2,0,5,0,,,19,3,,,,,,,,,,,2,0,,,,,,,,,,,,,3,3,,,,,,,,,1,0,4,0,,,9,0,,,,,,,10,5,16,5,10,0,,,,,1,1,1,0,2,0,,,,,,,3,3,,,,,5,1,4,0,,,,,,,,,,,,,,,,,,,,,,,5,0,2,0,,,,,,,,,,,,,1,1,,,3,3,,,,,4,2,,,2,0,,,,
124,91,23,2018-Hansen-Ann Oncol,Pembrolizumab,PD-1,Prostate adenocarcinoma,GU cancer,1b,23,2054806,KEYNOTE-028,,No,10 mg/kg Q2W,Treatment-related; ? 2 Patients (any grade) or ? 1 Patient (grade 3-4),1,0,0,Yes,14,3,0,,,,,,,,,,,,2,1,2,0,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,3,0,,,2,0,,,,,,,,,,,,,,,,,2,1,,,,,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,,,,2,1,,,1,1,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
125,92,50,2018-Necchi-J Clin Oncol,Pembrolizumab,PD-1,Urothelial bladder carcinoma,GU cancer,2,50,2736266,,PURE-01,No,200 mg Q3W,All treatment-related,0,0,0,No,,,,,,,,,,,3,0,,,,,3,0,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,1,0,,,,,,,,,,,3,0,6,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
126,93,25,2018-Rugo-Clin Cancer Res,Pembrolizumab,PD-1,Breast cancer,Other cancer,1b,25,2054806,KEYNOTE-028,,No,10 mg/kg Q2W,Treatment-related; ? 2 Patients (any grade) or ? 1 Patient (grade 3-4),1,0,0,Yes,16,4,0,,,,,,,,,,,,3,0,2,0,,,,,,,,,,,,,2,0,,,,,,,,,,,,,,,,,2,0,,,5,1,,,,,,,,,1,1,,,,,,,1,1,,,,,,,,,,,,,,,,,,,,,2,0,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
127,94,294,2018-Shitara-Lancet,Pembrolizumab,PD-1,Gastric or gastro-oesophageal junction cancer ,GI cancer,3,294,2370498,KEYNOTE-061,,No,200 mg Q3W,"Treatment-related ? 10% Patients (any grade) in either group or AEs of special interest (based on their likely immune aetiology, irrespective of attribution to study treatment)",29,29,0,Yes,155,42,2,"1 colitis, 1 interstitial lung disease",5,0,,,,,,,,,35,7,,,,,,,,,,,,,,,,,,,,,,,8,2,,,,,,,,,24,2,,,17,1,,,16,1,,,,,3,1,,,,,,,,,0,0,,,,,,,4,4,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,1,0,,,23,0,12,0,,,,,4,2,,,1,0,,,,,,,,,,,,,10,7,,,,,,,,
128,95,104,2018-Zhu-Lancet Oncol,Pembrolizumab,PD-1,Hepatocellular carcinoma,GI cancer,2,104,2702414,KEYNOTE-224,,No,200 mg Q3W,Treatment-related; ? 10% Patients (grade 1-2) or ? 1 Patient (grade 3-5),10,0,0,Yes,76,27,1,Ulcerative oesophagitis,,,,,,,,,,,22,4,12,0,,,,,,,,,,,,,1,1,,,,,,,,,5,1,,,,,,,7,1,,,8,0,,,11,0,,,,,,,9,4,14,7,,,1,1,,,,,,,5,2,,,,,,,7,1,,,,,5,0,10,0,5,0,,,,,,,,,,,,,7,0,,,,,,,6,0,,,,,,,,,3,2,1,1,,,,,,,,,,,,,3,1,,,,,,,,
129,96,277,2014-Herbst-Nature,Atezolizumab,PD-L1,Advanced incurable cancers,Mixed cancer types,1a,277,1375842,,PCD4989g  2011-001422-23  GO27831,Yes,mixed,Treatment-related; ? 4% Patients (any grade) and ? 2 Patients (grade 3-4),11,1,0,Unknown,194,35,,,,,,,16,1,32,0,19,0,67,5,23,0,,,,,,,,,,,,,,,,,,,,,,,15,2,,,,,,,33,0,,,32,1,11,1,29,0,,,,,,,6,3,4,3,,,,,,,,,,,,,,,,,15,1,13,0,,,,,22,0,29,0,,,,,12,0,,,,,21,1,,,15,2,,,,,,,,,,,,,,,,,,,,,,,4,2,,,,,,,,,,,,,,,4,2,2,2
130,97,142,2016-Fehrenbacher-Lancet,Atezolizumab,PD-L1,NSCLC,Lung cancer,2,142,1903993,POPLAR,GO28753  2013-001142-34 ,No,1200 mg Q3W,Treatment-related; ? 10% Patients in either group (any grade),14,14,0,Unknown,95,16,1,cardiac failure,,,,,,,,,,,29,,,,,,,,,,,,,,,,,,,,,,,,4,1,,,,,,,,,25,,,,17,,8,,10,,7,,,,2,1,6,3,6,3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,,,,,,9,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8,,,,1,,,,,
131,98,70,2016-McDermott-J Clin Oncol,Atezolizumab,PD-L1,RCC,GU cancer,1a,70,1375842,,PCD4989g  2011-001422-23  GO27831 ,Yes,mixed,Treatment-related; ? 2 Patients (all grades) and ? 1 Patient (grade 3-4),1,0,0,Unknown,59,12,0,,,,,,8,1,8,0,8,0,20,3,8,0,,,2,0,,,,,2,0,3,0,3,0,,,,,4,0,2,0,4,1,2,0,,,,,11,0,2,1,9,0,4,0,8,0,2,0,,,,,,,,,,,,,,,,,,,,,,,,,3,0,3,0,,,2,0,10,0,10,0,,,3,0,6,0,,,,,5,1,,,5,0,,,,,,,6,0,,,,,,,,,,,,,,,,,,,,,,,,,8,3,,,,,,,2,2
132,99,310,2016-Rosenberg-Lancet,Atezolizumab,PD-L1,Urothelial carcinoma,GU cancer,2,310,2108652,,GO29293 (Cohort 2)  IMvigor 210  2013-005486-39 ,No,1200 mg Q3W,Treatment-related,0,0,0,Unknown,215,50,0,,,,,,,,28,1,,,93,5,31,1,,,,,,,,,,,,,,,3,3,5,2,,,7,2,10,2,,,,,,,36,2,,,42,0,18,1,24,1,,,,,3,2,,,10,2,,,,,,,,,,,,,,,,,,,,,,,,,21,2,23,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9,3,,,,,,,,
133,100,119,2017-Balar-Lancet,Atezolizumab,PD-L1,Urothelial carcinoma,GU cancer,2,119,2108652,,GO29293 (Cohort 2)  IMvigor 210  2013-005486-39 ,No,1200 mg Q3W,Treatment-related; ? 3 Patients (any grade) and ? 1 Patient (grade 3-4),2,0,0,Unknown,79,19,1,sepsis,4,0,1,1,3,0,6,0,6,0,36,4,14,1,,,,,,,,,3,0,,,,,,,3,1,,,,,4,0,,,,,,,11,1,,,6,0,6,0,14,2,,,,,1,1,5,4,4,3,4,1,,,,,,,1,1,4,2,,,,,,,,,,,3,0,5,0,6,1,5,0,,,,,,,,,3,0,,,3,0,,,,,,,8,0,,,,,,,,,,,,,,,,,,,,,,,,,6,1,,,,,,,3,2
135,101,6,2016-Mizugaki-Invest New Drugs,Atezolizumab,PD-L1,Advanced solid tumors,Mixed cancer types,1,3,, ,,Yes,10 mg/kg Q3W,? 2 Patients,1,1,0,No,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,0,1,0,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
136,101,,2016-Mizugaki-Invest New Drugs,Atezolizumab,PD-L1,Advanced solid tumors,Mixed cancer types,1,3,, ,,,20 mg/kg Q3W,? 2 Patients,1,1,0,No,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,0,1,0,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
137,102,659,2017-Peters-J Clin Oncol,Atezolizumab,PD-L1,NSCLC,Lung cancer,2,659,2031458,BIRCH,,No,1200 mg Q3W,Treatment-related ? 5% Patients; Combined with special interest AEs > 1% Patients,32,32,0,Unknown,429,81,,,,,,,,,54,1,,,122,7,65,0,,,,,,,,,,,,,,,,,,,,,26,11,,,,,,,,,53,1,,,73,4,,,71,2,,,,,10,3,23,2,26,5,,,,,,,,,,,,,,,,,,,,,,,,,39,2,70,9,13,2,,,,,,,,,,,,,50,3,,,15,0,,,30,2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
138,103,609,2017-Rittmeyer-Lancet,Atezolizumab,PD-L1,NSCLC,Lung cancer,3,609,2008227,,,No,1200 mg Q3W,Treatment-related; ? 10% Patients in any group (any grade),60,60,0,Unknown,390,90,0,,,,,,,,108,1,,,163,17,,,,,,,,,,,,,19,1,,,,,,,54,1,,,118,15,141,2,,,,,143,2,,,108,4,74,2,94,4,107,2,,,,,,,,,,,,,,,,,,,,,,,,,,,39,1,,,67,7,73,3,,,,,,,,,,,3,0,,,,,116,8,18,0,24,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,70,14,,,10,3,,,,
139,104,32,2018-Colevas-Ann Oncol,Atezolizumab,PD-L1,Head and neck carcinoma,Other cancer,1,32,1375842,,,No,mixed,Treatment-related; ? 5% Patients (any grade) or ? 1 Patient (grade 3-4),1,0,0,Yes,21,4,0,,,,,,3,0,3,0,2,0,7,0,2,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,0,2,0,3,0,,,2,0,1,1,,,,,,,,,,,,,,,,,,,,,2,0,2,0,,,,,,,5,0,,,,,,,,,,,,,,,3,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,,
140,105,116,2018-Emens-JAMA Oncol,Atezolizumab,PD-L1,Breast cancer,Other cancer,1,116,1375842,,,No,mixed,Treatment-related; ? 3% Patients (any grade),3,3,0,Yes,73,13,2,"1 pulmonary hypertension, 1 cause not specified",,,,,9,0,19,0,,,15,1,11,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9,0,,,13,1,8,1,12,1,,,,,,,5,0,5,0,,,,,,,,,,,,,,,,,3,0,4,1,,,,,4,1,10,0,,,,,,,,,,,6,0,3,0,11,0,,,,,,,5,0,,,,,,,,,,,,,,,,,,,,,,,,,5,2,,,3,1,3,1,,
141,106,89,2018-Horn-Eur J Cancer,Atezolizumab,PD-L1,NSLCL,Lung cancer,1,89,1375842,,PCD4989g,No,mixed,Treatment-related; > 5% Patients (any grade),4,4,0,Yes,68,10,0,,,,,,,,6,0,,,18,2,,,,,,,,,,,,,,,,,,,,,,,,,7,2,,,,,,,12,0,,,14,1,6,1,7,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5,0,8,0,,,,,,,,,,,6,0,,,9,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
142,107,16,2018-Lukas-J Neurooncol,Atezolizumab,PD-L1,Glioblastoma,Other cancer,1a,16,1375842,,PCD4989g,No,2000 mg Q3W,Treatment-related,0,0,0,Yes,10,3,0,,,,,,,,,,,,4,0,,,,,,,3,0,,,1,0,,,,,,,,,,,,,,,,,,,,,1,0,1,0,2,0,1,0,2,0,1,0,,,,,1,0,1,1,,,,,,,,,,,,,,,,,,,1,0,,,1,0,1,0,,,1,0,,,,,,,,,2,0,,,2,2,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
143,108,103,2018-McDermott-Nat Med,Atezolizumab,PD-L1,RCC,GU cancer,2,103,1984242,,IMmotion150,No,1200 mg Q3W,"All-cause AEs ? 20% Patients (any grade) in any group or AEs of special interest (based on their likely immune aetiology, ",20,20,0,Yes,86,17,0,,,,,,,,25,,,,49,,16,,,,,,,,,,,,3,,4,,6,,,,,,1,0,,,23,,,,,,10,,,,19,,9,,17,,14,,,,0,0,,,,,,,,,,,,,,,,,9,3,,,,,,,,,,,15,,21,,,,,,,,,,,,15,,,,,,3,,,,,,15,0,5,0,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,
144,109,95,2018-Petrylak-JAMA Onc,Atezolizumab,PD-L1,Urothelial carcinoma,GU cancer,1,95,1375842,,PCD4989g,No,mixed,Treatment-related; ? 3% Patients (any grade) or ? 1% Patients (grade 3-4),2,0,0,Yes,64,9,0,,,,,,4,0,7,0,3,0,17,0,12,0,,,,,,,,,,,,,,,,,,,,,,,,,3,0,,,,,12,0,,,11,0,,,7,0,,,,,,,4,1,4,2,,,2,1,,,,,,,,,,,,,,,4,0,,,,,6,0,8,0,2,1,,,4,0,,,,,,,,,13,2,3,0,,,,,5,0,,,,,,,,,,,,,,,,,,,,,,,,,4,1,2,1,1,1,,,,
146,110,459,2018-Powles-Lancet,Atezolizumab,PD-L1,Urothelial carcinoma,GU cancer,3,459,2302807,,IMvigor211,No,1200 mg Q3W,Treatment-related; ? 5% Patients (any grade) or ? 2% Patients (grade 3-4) in either group,22,9,0,Yes,319,91,4,"1 general physical health deterioration, 1 respiratory failure, 1 intestinal perforation, 1 toxic epidermal necrolysis",,,,,,,40,,,,71,7,55,,12,,,,,,,,,,10,,,,,,,,,,,,18,,,,,,,,56,,,,46,,16,,50,,29,0,9,,,,,,,,,,,,,,,,,,,,,,,,,,13,,,,,,17,,40,,,,,,,,,,0,0,,,,,51,8,6,,3,1,,,,,,,,,,,,,,,,,,,,,,,,,,0,,,25,9,,,3,2,,,,
147,111,88,2016-Kaufman-Lancet Oncol,Avelumab,PD-L1,Merkel cell carcinoma,Other cancer,2,88,2155647,,,No,10 mg/kg Q2W,Treatment-related; ? 5% Patients (any grade) and ? 1 Patient (grade 3-5),4,0,0,No,62,5,0,,15,0,,,,,,,,,21,0,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,5,0,,,8,0,,,8,0,,,,,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,6,0,5,0,,,,,,,,,,,,,7,0,,,,,,,3,0,2,0,,,,,,,,,1,0,,,,,,,2,1,,,,,,,2,2,,,,,,
148,112,44,2017-Apolo-J Clin Oncol,Avelumab,PD-L1,Urothelial carcinoma,GU cancer,1b,44,1772004,,,No,10 mg/kg Q2W,Treatment-related; > 5% Patients (any grade) and ? 1 Patient (grade ? 3),2,0,0,Unknown,29,3,0,,9,0,,,,,,,,,9,0,3,0,,,,,,,1,0,,,,,,,,,,,,,1,0,,,,,,,,,2,1,,,5,0,,,4,0,,,,,,,1,0,2,1,,,,,,,,,,,,,,,,,,,,,,,,,,,4,0,,,,,,,,,,,,,,,5,1,,,,,,,3,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
150,113,184,2017-Gulley-Lancet Oncol,Avelumab,PD-L1,NSCLC,Lung cancer,1b,184,1772004,,,No,10 mg/kg Q2W,Treatment-related; ? 5% Patients (any grade) and ? 1 Patient (grade ? 3),9,0,0,Yes,142,22,1,Radiation pneumonitis,38,4,,,,,,,12,0,46,0,,,,,,,,,,,,,1,0,,,1,1,,,,,1,1,6,2,,,,,,,13,0,,,23,0,9,0,13,0,5,2,,,,,,,,,,,2,1,,,4,3,,,,,,,,,,,,,,,,,9,0,,,,,,,,,,,,,,,,,,,,,,,,,11,0,,,,,,,,,2,0,,,,,,,,,,,,,,,7,1,,,1,1,1,1,,
151,114,15,2017-Heery-Lancet Oncol,Avelumab,PD-L1,Advanced solid tumors,Mixed cancer types,1a,15,1772004,,,Yes,10 mg/kg Q2W,Treatment-related; ? 10% Patients (any grade) and ? 1 Patient (grade ? 3),1,0,0,No,14,5,0,,1,0,,,3,0,4,0,2,0,11,1,,,,,0,0,0,0,,,,,,,,,,,0,0,,,,,,,,,,,,,,,,,2,0,,,2,0,,,,,,,1,1,1,1,0,0,,,,,0,0,0,0,,,,,,,,,0,0,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,,2,0,,,,,,
152,115,184,2018-Bang-Ann Oncol,Avelumab,PD-L1,Gastric or gastro-oesophageal junction cancer,GI cancer,3,184,2625623,,JAVELIN Gastric 300,No,10 mg/kg Q2W,Treatment-related; > 10% Patients (any grade) or > 1% Patients (grade 3),18,1,0,Yes,90,17,0,,39,1,,,,,,,,,11,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6,0,,,12,0,8,0,11,1,,,,,,,6,3,7,4,3,2,4,4,,,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,7,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,1,0,,,0,0,,,,
153,116,393,2018-Barlesi-Lancet Oncol,Avelumab,PD-L1,NSLCL,Lung cancer,3,393,2395172,,JAVELIN Lung 200,No,10 mg/kg Q2W,Treatment-related; ? 10% Patients (grade 1-2) and ? 1% Patient (grade 3-5),39,3,0,Yes,251,39,0,,65,6,,,,,,,,,30,1,,,,,,,,,,,,,3,0,,,,,,,,,,,,,,,2,0,,,34,0,,,20,0,,,24,0,,,,,,,,,,,,,,,,,5,4,,,,,,,,,,,6,0,,,,,,,,,,,,,,,,,0,0,,,,,30,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,5,0,,,1,0,,,,
154,117,39,2018-DAngelo-JAMA Oncol,Avelumab,PD-L1,Merkel cell carcinoma,Other cancer,2,39,2155647,,JAVELIN Merkel 200 part B ,No,10 mg/kg Q2W,Treatment-related; ? 5% Patients (any grade) or ? 1 Patient (grade 3-4),1,0,0,Yes,28,8,0,,9,1,,,,,2,0,2,0,9,0,2,0,2,0,,,,,,,2,0,,,,,,,,,,,,,2,0,,,,,,,,,,,2,0,,,2,0,,,,,,,3,1,1,1,,,,,,,3,1,,,,,,,,,,,,,,,,,2,0,,,2,0,,,,,,,,,,,,,3,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
149,118,168,2018-Dirix-Breast Cancer Res Treat,Avelumab,PD-L1,Breast cancer,Other cancer,1b,168,1772004,JAVELIN,,No,10 mg/kg Q2W,Treatment-related; ? 5% Patients (any grade) or ? 1 Patient (grade ? 3),8,0,0,Yes,115,21,2,1 acute hepatic failure and 1 respiratory distress,24,0,,,11,0,,,,,32,3,,,,,,,,,,,,,,,,,,,,,,,3,1,5,1,,,,,3,1,12,0,,,22,0,,,15,0,,,,,,,3,1,4,1,,,4,3,,,,,,,,,3,3,,,,,,,,,,,13,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,3,,,1,1,,,,
155,119,25,2018-Le Tourneau-J Immunother Cancer,Avelumab,PD-L1,Adrenocortical carcinoma,Other cancer,1b,25,1772004,,JAVELIN Solid Tumor,No,10 mg/kg Q2W,Treatment-related; ? 10% Patients (any grade) or ? 1 Patient (grade 3) in either group,2,0,0,Yes,20,2,0,,4,0,,,,,2,0,2,0,4,0,,,,,,,,,,,,,,,,,,,,,,,2,1,,,,,,,,,,,,,3,0,4,0,2,0,,,,,,,1,0,1,0,,,0,0,,,,,,,,,,,0,0,,,,,,,0,0,,,,,,,,,,,,,,,,,,,1,0,,,,,,,4,0,,,,,,,,,1,0,,,,,,,,,,,,,,,2,0,0,0,,,,,2,1
156,120,61,2016-Massard-J Clin Oncol,Durvalumab,PD-L1,Urothelial Bladder Cancer,GU cancer,2-Jan,61,1693562,,,No,10 mg/kg Q2W,Treatment-related; ? 5% patients or ? 1 Patient (grade ? 3) or ? 2 Patients (AESIs),3,0,0,Yes,39,3,0,,2,1,,,,,4,0,,,8,0,2,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5,0,,,4,0,,,6,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,0,,,,,,,,,,,,,,,,,4,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
157,121,475,2017-Antonia-N Engl J Med,Durvalumab,PD-L1,NSCLC,Lung cancer,3,475,2125461,PACIFIC,,No,10 mg/kg Q2W,Treatment-related; ? 5% Patients in either group,23,23,0,Yes,322,56,7,"(n=4) pneumonitis and (n=1 each with the following) cardiomyopathy, right ventricular failure, respiratory distress, respiratory failure, brain natriuretic peptide increased, and radiation pneumonitis",,,,,,,,,,,62,1,33,0,,,,,,,,,,,,,,,,,,,,,43,6,28,3,25,0,,,,,27,0,,,26,0,,,46,2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,37,1,,,,,,,,,,,,,,,28,3,,,,,,,50,1,30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
159,122,970,2017-Powles-JAMA Oncol,Durvalumab,PD-L1,Solid cancer (exclude patients in the UC cohort),Mixed cancer types,,779,,,,No,10 mg/kg Q2W,Treatment-related; ? 5% Patients in either group (all grades) and ? 1 Patient in UC cohort (grade ? 3),38,0,0,,449,79,2,,9,1,,,,,20,0,,,148,16,59,1,,,,,,,,,,,,,,,5,1,,,,,,,,,,,,,,,51,3,,,69,2,,,64,4,,,,,,,28,7,32,8,11,1,16,6,,,,,,,,,2,2,3,1,,,,,,,,,38,2,50,1,17,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19,1,,,,,,,,
160,122,,2017-Powles-JAMA Oncol,Durvalumab,PD-L1,Urothelial carcinoma,GU cancer,2-Jan,191,1693562,,CD-ON-MEDI4736-1108,,10 mg/kg Q2W,Treatment-related; ? 5% Patients in either group (all grades) and ? 1 Patient in UC cohort (grade ? 3),9,0,0,Yes,116,13,2,1 each due to autoimmune hepatitis and pneumonitis,2,1,,,,,11,0,,,37,0,10,0,,,,,,,,,,,,,,,3,2,,,,,,,,,,,,,,,18,0,,,13,0,,,16,1,,,,,,,8,2,6,3,4,1,6,2,,,,,,,,,2,1,2,1,,,,,,,,,11,0,14,0,2,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,1,,,,,,,,
161,123,444,2018-Garassino-Lancet Oncol,Durvalumab,PD-L1,NSCLC,Lung cancer,2,444,2087423,,ATLANTIC,No,10 mg/kg Q2W,Treatment-related; ? 10% Patients (grade 1-2) or ? 1 Patient (grade 3-4) in any corhot,44,0,0,Yes,256,40,0,,6,3,,,,,,,,,50,2,28,0,,,,,6,1,,,,,,,,,,,3,1,,,9,4,,,,,,,,,,,,,28,1,14,2,27,3,,,1,1,,,,,6,2,,,6,4,,,,,,,,,,,2,2,,,,,,,,,,,,,6,1,,,,,,,,,,,,,31,1,,,,,,,36,0,,,,,,,,,2,1,,,1,1,,,,,,,,,,,9,1,2,1,1,1,,,,
162,124,11,2018-Necchi-Eurology,Durvalumab,PD-L1,Germ cell tumors,GU cancer,2,11,3081923,,APACHE,No,1500 mg Q4W,,0,0,0,Yes,,,0,,,,,,,,,,,,1,0,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
163,125,65,2018-Siu-JAMA Oncol,Durvalumab,PD-L1,Head and neck carcinoma,Other cancer,2,65,2319044,,CONDOR,No,10 mg/kg Q2W,Treatment-related; > 5% Patients (any grade) or > 2% Patients (grade 3-4) in any arm,3,1,0,Yes,41,8,0,,,,,,,,0,0,,,12,2,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,,,,1,,1,,7,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,5,0,,,,,,,7,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,
